

GenCore version 5.1.5
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 1, 2003, 14:56:34 ; Search time 413.564 Seconds
(without alignments)
10776.324 Million cell updates/sec

Title: US-09-625-573-3

Perfect score: 1979
Sequence: 1 CAGAGCTGCTGACACAGC.....ATATGCATATATAATTTAG 1979

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : N_Geneseq_101002.*

- 1: /SID22/gcgdata/geneseq/geneseq-nbml/NA1980.DAT.*
- 2: /SID22/gcgdata/geneseq/geneseq-nbml/NA1981.DAT.*
- 3: /SID22/gcgdata/geneseq/geneseq-nbml/NA1982.DAT.*
- 4: /SID22/gcgdata/geneseq/geneseq-nbml/NA1983.DAT.*
- 5: /SID22/gcgdata/geneseq/geneseq-nbml/NA1984.DAT.*
- 6: /SID22/gcgdata/geneseq/geneseq-nbml/NA1985.DAT.*
- 7: /SID22/gcgdata/geneseq/geneseq-nbml/NA1986.DAT.*
- 8: /SID22/gcgdata/geneseq/geneseq-nbml/NA1987.DAT.*
- 9: /SID22/gcgdata/geneseq/geneseq-nbml/NA1988.DAT.*
- 10: /SID22/gcgdata/geneseq/geneseq-nbml/NA1989.DAT.*
- 11: /SID22/gcgdata/geneseq/geneseq-nbml/NA1990.DAT.*
- 12: /SID22/gcgdata/geneseq/geneseq-nbml/NA1991.DAT.*
- 13: /SID22/gcgdata/geneseq/geneseq-nbml/NA1992.DAT.*
- 14: /SID22/gcgdata/geneseq/geneseq-nbml/NA1993.DAT.*
- 15: /SID22/gcgdata/geneseq/geneseq-nbml/NA1994.DAT.*
- 16: /SID22/gcgdata/geneseq/geneseq-nbml/NA1995.DAT.*
- 17: /SID22/gcgdata/geneseq/geneseq-nbml/NA1996.DAT.*
- 18: /SID22/gcgdata/geneseq/geneseq-nbml/NA1997.DAT.*
- 19: /SID22/gcgdata/geneseq/geneseq-nbml/NA1998.DAT.*
- 20: /SID22/gcgdata/geneseq/geneseq-nbml/NA1999.DAT.*
- 21: /SID22/gcgdata/geneseq/geneseq-nbml/NA2000.DAT.*
- 22: /SID22/gcgdata/geneseq/geneseq-nbml/NA2001A.DAT.*
- 23: /SID22/gcgdata/geneseq/geneseq-nbml/NA2001B.DAT.*
- 24: /SID22/gcgdata/geneseq/geneseq-nbml/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	1977.4	99.9	1979	16	Human monocytic che
2	1943.8	98.2	143068	21	Human low adenosin
3	1943.8	98.2	143068	21	Human low adenosin
4	1943.8	98.2	143068	21	Human adenosine re
5	1943.8	98.2	143068	21	Human adenosine re
6	1943.8	98.2	143068	24	Ovary cancer relat
7	1943.8	98.2	149412	21	Human adenosine re
8	1943.8	98.2	152740	21	Human low adenosin
9	1313	66.3	10528	24	Human immune syste

c	10	1286.4	65.0	10528	24	ABL323335	Human immune syste
	11	1083	54.7	1083	22	AAS12140	Human wild-type CC
	12	1081.4	54.6	1083	22	AAS12139	Human CCR2-641 pol
	13	1079.8	54.6	1083	23	ABI97976	Non-endogenous hum
	14	1078.2	54.5	1083	18	AAT96976	Human monocytic che
	15	980	49.5	2232	16	AAQ96297	Macaque chemokine
	16	704.6	35.6	1059	18	AAT85163	DNA encoding human
	17	703.4	35.5	1225	19	AAT76920	Human CC chemokine
	18	703.4	35.5	1225	24	ABA02317	Human HIV-1 co-rec
	19	703.4	35.5	1225	22	AAH26903	cDNA for human CCR
	20	703.4	35.5	1477	18	AAT90117	Human CCR5 cDNA se
	21	703.4	35.5	1477	22	AAF87099	Human chemokine re
	22	703.4	35.5	3383	18	AAT85161	Human low adenosin
	23	703.4	35.5	3383	21	AAF21271	Human adenosine re
	24	703.4	35.5	3383	21	AAA35149	Human chemokine re
	25	703.4	35.5	3383	22	AAD08577	Human chemokine (C
	26	703.4	35.5	9141	24	ABA97318	HIV-1 co-receptor
	27	702	35.5	1376	20	AAV84126	Human CCR5 Gln 55
	28	701.8	35.5	1225	24	ABA02318	Human HDNR10 cDNA
	29	701.8	35.5	1414	22	AAF26390	Nucleotide sequenc
	30	701.4	35.4	1059	22	AAI65463	Human G-protein ch
	31	700.2	35.4	1414	18	AAI44042	Human G-protein ch
	32	700.2	35.4	1414	21	AAZ91481	Human G-protein ch
	33	700.2	35.4	1414	22	AAI13181	Human G-protein ch
	34	700.2	35.4	1414	22	AAI13282	Human G-protein ch
	35	700.2	35.4	1414	24	ABK51853	DNA encoding human
	36	700	35.4	1059	19	AAV23992	Human CC-CR5 codi
	37	700	35.4	1059	24	ABA97319	Human chemokine (C
	38	700	35.4	1071	20	AAV84125	HIV-1 co-receptor
	39	699.2	35.3	5674	20	AAZ24738	Human chemokine re
	40	697.6	35.3	1056	22	AAI13198	Human G-protein ch
	41	697.6	35.3	1056	22	AAI13299	Human G-protein ch
	42	697.6	35.3	1056	24	ABK51870	DNA encoding human
	43	696.8	35.2	1059	23	ABI97978	Non-endogenous hum
	44	692.2	35.0	1255	19	AAT76919	DNA encoding human
	45	683.4	34.5	1344	20	AAV84159	HIV-1 co-receptor

ALIGNMENTS

RESULT 1
AAQ96298
ID AAQ96298 standard; cDNA; 1979 BP.

XX AC AAQ96298;
XX AC AAQ96298;

XX DT 29-DEC-1995 (first entry)

XX DE Human monocytic chemoattractant protein-1 receptor MCP-1RB.

XX DE Monocyte chemoattractant protein-1 receptor; MCR-1R; chemokine; ss.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers
XX CDS 81..1160
XX FT /*tag= a

XX PN WO9519436-A.

XX XX 20-JUL-1995.

XX PF 11-JAN-1995; 95WO-US00476.

XX PR 13-JAN-1994; 94US-0182962.

XX PA (REGC) UNIV CALIFORNIA.

XX PI Charo I, Coughlin S;

XX XX WPI; 1995-263866/34.

XX DR P-PSDB; AAR9166.

XX

DNA encoding monocyte chemo-attractant protein-1 receptor - used partic.
for identifying antagonists and for treating diseases characterised by
monocytic infiltrates

Disclosure; Fig 2; 84pp; English.

To identify and clone new members of the chemokine receptor gene
family, degenerate oligo primers were designed corresp. to the
conserved sequences R79167 in the second and R79168 in the third
transmembrane domains of the MIP-lalpha/RANTES receptor, the IL-8
receptors and the HUMSTRS orphan receptor (GenBank Accession #99293.
The degenerate oligo incorporating EcoRI and XhoI sites at their 5',
ends are Q96299 and Q96300. Amplification of cDNA derived from MM6
cells with the primers yielded a number of PCR products. One cDNA
appeared to encode a novel protein. To obtain a full-length version
of this clone, a MM6 cDNA library was constructed in pPROG and probed
with the PCR product. A 2.1 kb cDNA library was obtained. Analysis of
additional clones in the MM6 cDNA library revealed a second
sequence that was identical to the 2.1 kb cDNA sequence first obtained.
from the 5' UTR through the putative seventh transmembrane domain
but contained a different cytoplasmic tail. The second sequence
appears to represent alternative splicing of the carboxyl-terminal
tail of the MCP-1R protein. The two sequences are denoted MCP-1RA
and MCP-1RB (see Q96297/R79165 & Q96298/R79166). Active mature
MCP-1RA has a predicted mol. wt. of about 42,000 daltons. MCP-1RB
has a mol. wt. of about 41,000 daltons.

Sequence 1979 BP; 530 A; 434 C; 452 G; 563 T; 0 other;

Query Match 99.9%; Score 1977.4; DB 16; Length 1979;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 1978; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CAGGACTGCTGAGACAGCCACAGCTGAACAGAGAGAAAGTGGATTGAACAAGACGCAT 60
DB 1 CAGGACTGCTGAGACAGCCACAGCTGAACAGAGAGAAAGTGGATTGAACAAGACGCAT 60
QY 61 TTCGCCAGTACATCCACACATGCTGTCCACATCTCGTCTCGGTTTATCAGAAATACCA 120
DB 61 TTCGCCAGTACATCCACACATGCTGTCCACATCTCGTCTCGGTTTATCAGAAATACCA 120
QY 121 ACGAGAGCGGTGAAGAAGTACACACTTTTGTGATTGATTACGCTGCTCCCTGTTCATA 180
DB 121 ACGAGAGCGGTGAAGAAGTACACACTTTTGTGATTGATTACGCTGCTCCCTGTTCATA 180
QY 181 AATTGACGTGAGCAAAATTTGGGCGCCAACTCCTCGCTCCGCTCTACTCGTGGTGTCA 240
DB 181 AATTGACGTGAGCAAAATTTGGGCGCCAACTCCTCGCTCCGCTCTACTCGTGGTGTCA 240
QY 241 TCTTTGGTTTGTGGGCAACATGCTGCTCCTCATCTTATTAACACTGCAAAAGCTGA 300
DB 241 TCTTTGGTTTGTGGGCAACATGCTGCTCCTCATCTTATTAACACTGCAAAAGCTGA 300
QY 301 AGTGCTGACGTGACATTTACCTGCTCAACCTGGCCATCTCTGATCTGCTTTTCTTATTA 360
DB 301 AGTGCTGACGTGACATTTACCTGCTCAACCTGGCCATCTCTGATCTGCTTTTCTTATTA 360
QY 361 CTCGCCATTTGGGCTCACHCTGCTGCAAAATGAGTGGGCTCTTTGGGAATGCAATGTGCA 420
DB 361 CTCGCCATTTGGGCTCACHCTGCTGCAAAATGAGTGGGCTCTTTGGGAATGCAATGTGCA 420
QY 421 AATTATTACAGAGGCTGTATCACATCGGTTATTTGGCGGAATCTTCTTCATCATCTCC 480
DB 421 AATTATTACAGAGGCTGTATCACATCGGTTATTTGGCGGAATCTTCTTCATCATCTCC 480
QY 481 TGACAAATCGATAGATACCTGGCTATTGTCCATGCTGTGTTTAAAGCCAGGACGG 540
DB 481 TGACAAATCGATAGATACCTGGCTATTGTCCATGCTGTGTTTAAAGCCAGGACGG 540
QY 541 TCACCTTTGGGCTGACACAGTGTGATCACCTGGTGGTGGCTGTGTTTCTGTGCC 600
DB 541 TCACCTTTGGGCTGACACAGTGTGATCACCTGGTGGTGGCTGTGTTTCTGTGCC 600

QY 601 CAGGAATCATCTTTACTAAATGCCAGAAAGAAATCTGTATTATGTCTGTGGCCCTTATT 660
DB 601 CAGGAATCATCTTTACTAAATGCCAGAAAGAAATCTGTATTATGTCTGTGGCCCTTATT 660
QY 661 TTCCACGAGGATGGAATAATTTCCACACAATAATGAGAAACATTTTCGGGCTGTCTGTC 720
DB 661 TTCCACGAGGATGGAATAATTTCCACACAATAATGAGAAACATTTTCGGGCTGTCTGTC 720
QY 721 CGCTGCTCATATGTCATCTGCTACTCGGGAATCTCTGAAACCCCTCTTCGGTGTGCGAA 780
DB 721 CGCTGCTCATATGTCATCTGCTACTCGGGAATCTCTGAAACCCCTCTTCGGTGTGCGAA 780
QY 781 ACGAAGAAGAGGAGGATAGGCGAGTCACTCATCTCCACCATCATGATTTGTTTACTTTC 840
DB 781 ACGAAGAAGAGGAGGATAGGCGAGTCACTCATCTCCACCATCATGATTTGTTTACTTTC 840
QY 841 TCTTCTGGACTCCCTATAACATTTGTCATCTCTGTAACACCTTCCAGGAATTTCTTCGGCC 900
DB 841 TCTTCTGGACTCCCTATAACATTTGTCATCTCTGTAACACCTTCCAGGAATTTCTTCGGCC 900
QY 901 TGAGTAACTGTGAAAGCAGCAGTCAACTGAGCAAGCCAGCGAGTGACAGACTCTTGT 960
DB 901 TGAGTAACTGTGAAAGCAGCAGTCAACTGAGCAAGCCAGCGAGTGACAGACTCTTGT 960
QY 961 GGATGACTCACTGCTGCTCAATCCATCATCTATGCTTCTGTTGGGAGAACTTCAGAA 1020
DB 961 GGATGACTCACTGCTGCTCAATCCATCATCTATGCTTCTGTTGGGAGAACTTCAGAA 1020
QY 1021 GGTATCTCTCGGTGTTCTTCCGAAAGCACATCACCAGCGCTTCTGCAACAATGTCCAG 1080
DB 1021 GGTATCTCTCGGTGTTCTTCCGAAAGCACATCACCAGCGCTTCTGCAACAATGTCCAG 1080
QY 1081 TTTTCTACAGGAGACAGTGGATGAGTGACTTCAACAACAGCGCTTCCACTGGGAGC 1140
DB 1081 TTTTCTACAGGAGACAGTGGATGAGTGACTTCAACAACAGCGCTTCCACTGGGAGC 1140
QY 1141 AGGAAGTCTCGCTGTTTATAAAGAGGAGGACGTTGATTGTTGTTTATAAAGGAGA 1200
DB 1141 AGGAAGTCTCGCTGTTTATAAAGAGGAGGACGTTGATTGTTGTTTATAAAGGAGA 1200
QY 1201 TAACAATCTGTATATAACAACAACCTTCAAGGGTTTGTGGAACAATAGAAACCTGTAAAG 1260
DB 1201 TAACAATCTGTATATAACAACAACCTTCAAGGGTTTGTGGAACAATAGAAACCTGTAAAG 1260
QY 1261 CAGGTGCCAGAACCTCAGGCTGTGTACTATAACAGACTATGTACCCCAATGTCATA 1320
DB 1261 CAGGTGCCAGAACCTCAGGCTGTGTACTATAACAGACTATGTACCCCAATGTCATA 1320
QY 1321 TCCAACATGTCTCAGGGAATAATCCAGAAAACCTGTGGGTAGAGACTTTGACTCTCCAG 1380
DB 1321 TCCAACATGTCTCAGGGAATAATCCAGAAAACCTGTGGGTAGAGACTTTGACTCTCCAG 1380
QY 1381 AAAGCTCATCTCAGCTCCTGAAAATGCGCTCATTTACCTGTGCTAATCCTCTTTTCTAG 1440
DB 1381 AAAGCTCATCTCAGCTCCTGAAAATGCGCTCATTTACCTGTGCTAATCCTCTTTTCTAG 1440
QY 1441 TCTTCAATTTCTTCACTCAATCTGTGATTCTGTCAATGCTTCAATCAGGCGCAGC 1500
DB 1441 TCTTCAATTTCTTCACTCAATCTGTGATTCTGTCAATGCTTCAATCAGGCGCAGC 1500
QY 1501 TGGAGGTGAAGAAGAAATGTGACAGGCACAGATGAATGGGAGTGAGGATAGTGGGCTC 1560
DB 1501 TGGAGGTGAAGAAGAAATGTGACAGGCACAGATGAATGGGAGTGAGGATAGTGGGCTC 1560
QY 1561 AGGGCTGAGAGGAGAGGAGGAGACATGAGCTGGCTGAGCCTGGGAGAAAGAAAGGT 1620
DB 1561 AGGGCTGAGAGGAGAGGAGGAGACATGAGCTGGCTGAGCCTGGGAGAAAGAAAGGT 1620
QY 1621 GAGCAAGGGCTCACCGATTCAGCAGGAGATGATGATGCTGCTTACGCCCATCTGCCAC 1680
DB 1621 GAGCAAGGGCTCACCGATTCAGCAGGAGATGATGATGCTGCTTACGCCCATCTGCCAC 1680

QY 1681 GTGATTTAACTTCAAGGTTCCAGGTCAGGAGAGTTGGCAACTGCAATAACCTG 1740
 |||||
 Db 1681 GTGATTTAACTTCAAGGTTCCAGGTCAGGAGAGTTGGCAACTGCAATAACCTG 1740
 |||||
 QY 1741 GGAGTTTGGTGGAGTCCGATGATTTCTTTTGCATAAGTCATGACATATTTTGGCTTT 1800
 |||||
 Db 1741 GGAGTTTGGTGGAGTCCGATGATTTCTTTTGCATAAGTCATGACATATTTTGGCTTT 1800
 |||||
 QY 1801 AFTACAGTTTATCTATGACACCCATGACCTTACATTTGAAATCTATGAAATATCATGCT 1860
 |||||
 Db 1801 AFTACAGTTTATCTATGACACCCATGACCTTACATTTGAAATCTATGAAATATCATGCT 1860
 |||||
 QY 1861 CAAATGTTTCAGATGCTTCTTAGGCCACATCCCTGCTCAAAATTCAGAAAATTTTGT 1920
 |||||
 Db 1861 CAAATGTTTCAGATGCTTCTTAGGCCACATCCCTGCTCAAAATTCAGAAAATTTTGT 1920
 |||||
 QY 1921 TTATAAAGATGCAATATCTATGATGCTATATATATATATGATGCAATATAAATTTAG 1979
 |||||
 Db 1921 TTATAAAGATGCAATATCTATGATGCTATATATATATATGATGCAATATAAATTTAG 1979
 |||||

RESULT 2
 AAF21105
 ID AAF21105 standard; DNA; 143068 BP.
 XX
 AC AAF21105;
 XX
 DT 14-MAR-2001 (first entry)
 XX
 DE Human low adenine antisense oligonucleotide related sequence #2672.
 XX
 KW Low adenine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.
 XX
 XX Homo sapiens.
 XX
 XX WO200062736-A2.
 XX
 XX 26-OCT-2000.
 XX
 XX 24-MAR-2000; 2000WO-US08020.
 XX
 XX 06-APR-1999; 99US-0127958.
 XX
 XX (UYEC-) UNIV EAST CAROLINA.
 XX (NYCE/) NYCE J W.
 XX
 XX Nyce JW;
 XX
 XX WPI; 2000-679539/66.
 XX
 XX Low adenine (A) content antisense oligonucleotides which do not
 XX trigger adenine receptors during metabolism, useful e.g. for treating
 XX cancers and respiratory obstructions -
 XX
 XX Disclosure; Page 924-957; 1592pp; English.
 XX
 XX The present invention describes low adenine (A) content antisense
 XX oligonucleotides and compositions (I) comprising them. In the antisense
 XX oligonucleotides the A is replaced by a 'Universal' or alternative base.
 XX (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 XX immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
 XX The antisense oligonucleotides and (I) can be used to down-regulate the
 XX expression and/or activity of target polypeptides associated with
 XX lung/respiratory disorders and malignancies, such as stimulating and

CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy (diseases
 CC and/or surfactant hypoproduction) which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
 CC fragments and antisense oligonucleotides used in the exemplification of
 CC the present invention.
 XX
 XX Sequence 143068 BP; 41194 A; 30122 C; 32403 G; 39349 T; 0 other;

Query Match 98.2%; Score 1943.8; DB 21; Length 143068;

Best Local Similarity 99.9%; Pred. No. 0;

Matches 1945; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 27 CTGAACAGAGAAAGTGGATTGAACAGGAGCGCATTTCCCCAGTACATCCACAAATCGTG 86
 |||||
 Db 46052 CAGAACAGAGAAAGTGGATTGAACAGGAGCGCATTTCCCCAGTACATCCACAAATCGTG 46111
 |||||
 QY 87 TCCACATCTCTGTTCTCGGTTTATCAGAAATACCAACAGAGCGGTGAAGTCAACACC 146
 |||||
 Db 46112 TCCACATCTCTGTTCTCGGTTTATCAGAAATACCAACAGAGCGGTGAAGTCAACACC 46171
 |||||
 QY 147 TTTTGGATATGATTAAGTACGGTGTCTCTGTCATATAAATTCAGCTGAGCAAAATTTGGGCC 206
 |||||
 Db 46172 TTTTGGATATGATTAAGTACGGTGTCTCTGTCATATAAATTCAGCTGAGCAAAATTTGGGCC 46231
 |||||
 QY 207 CAACCTCGCTCGCTCTACTCGTGTCTATCTTTGTTGTTGTTGGGCAACATGCTG 266
 |||||
 Db 46232 CAACCTCGCTCGCTCTACTCGTGTCTATCTTTGTTGTTGTTGGGCAACATGCTG 46291
 |||||
 QY 267 GTGCTCTCATCTTAATAAAGCTGCAAAAGCTGAAGTCTTGAAGTCAATTTACTGCTG 326
 |||||
 Db 46292 GTGCTCTCATCTTAATAAAGCTGCAAAAGCTGAAGTCTTGAAGTCAATTTACTGCTG 46351
 |||||
 QY 327 AACCTGGCCATCTCTGATCTGCTTTTCTTATTAATCTCTCCATTTGTTGGCTCACTCTGCT 386
 |||||
 Db 46352 AACCTGGCCATCTCTGATCTGCTTTTCTTATTAATCTCTCCATTTGTTGGCTCACTCTGCT 46411
 |||||
 QY 387 GCAATGAGTGGGCTTTTGGGAATGCAATGTGCAAAATTTATTCACAGGGCTGTATCACATC 446
 |||||
 Db 46412 GCAATGAGTGGGCTTTTGGGAATGCAATGTGCAAAATTTATTCACAGGGCTGTATCACATC 46471
 |||||
 QY 447 GGTATTTTGGCGGAATCTTCTTCATCATCTCTCTGCAAAATGATAGTACTGCTGCTATT 506
 |||||
 Db 46472 GGTATTTTGGCGGAATCTTCTTCATCATCTCTCTGCAAAATGATAGTACTGCTGCTATT 46531
 |||||
 QY 507 GTCCATGCTGTGTTGCTTTTAAAGCCAGAGCGGTCACTTTGGGTGGTGCACAAAGTGTG 566
 |||||
 Db 46532 GTCCATGCTGTGTTGCTTTTAAAGCCAGAGCGGTCACTTTGGGTGGTGGTGCACAAAGTGTG 46591
 |||||
 QY 567 ATCACTGTGTTGGTGTGTTGTTGTTCTCTGTCGCCAGGAATCATCTTTACTAAATGCCAG 626
 |||||
 Db 46592 ATCACTGTGTTGGTGTGTTGTTGTTCTCTGTCGCCAGGAATCATCTTTACTAAATGCCAG 46651
 |||||
 QY 627 AAAGAAGATCTGTTTATGCTGTGGCCCTTATTTTCCAGAGATGGAATAATTTCCAC 686
 |||||
 Db 46652 AAAGAAGATCTGTTTATGCTGTGGCCCTTATTTTCCAGAGATGGAATAATTTCCAC 46711
 |||||
 QY 697 ACAATAATGAGAAACATTTTGGGGCTGTTCTGTCGCCGCTGCTCATCATGTCATCTGCTAC 746

Db	46712	ACATTAATGAGAA	CAATTTGGGCTGGTCTCGCCGCTGCTCATCATGGTCATCTGCTAC	46771
QY	747	TGGGAATCCTGAAA	ACCCTGCTCGGTGTCGAAACGAGAAAGAGCATAGGCGACGTG	806
Db	46772	TGGGAATCCTGAAA	ACCCTGCTCGGTCTCGAAACGAGAAAGAGCATAGGCGACGTG	46831
QY	807	AGAGTCATCTTCA	CATCATGATGTTTACTTTCTTCTTGACATCCCTATAACATTTCTC	866
Db	46832	AGAGTCATCTTCA	CATCATGATGTTTACTTTCTTCTTGACATCCCTATAACATTTCTC	46891
QY	867	ATTCTCCTGAACA	CCCTTCCAGAAATTTCTTCGSCCTGAGTAACTGTGAAGCACAGTCAA	926
Db	46892	ATTCTCCTGAACA	CCCTTCCAGAAATTTCTTCGSCCTGAGTAACTGTGAAGCACAGTCAA	46951
QY	927	CTGGACCAAGCC	ACGAGAGACTCTTGGGATGACTCACTGCTGCATCAATCCC	986
Db	46952	CTGGACCAAGCC	ACGAGAGACTCTTGGGATGACTCACTGCTGCATCAATCCC	47011
QY	987	ATCATCTATGCC	TTCTGGGAGAGTTTCAGAGGTATCTCTCGGTGTTCTTCGGAAG	1046
Db	47012	ATCATCTATGCC	TTCTGGGAGAGTTTCAGAGGTATCTCTCGGTGTTCTTCGGAAG	47071
QY	1047	CACATCACCAGC	GTCTTCGAAACAATGTCCAGTTTTCTACGGGACAGTGGATGGA	1106
Db	47072	CACATCACCAGC	GTCTTCGAAACAATGTCCAGTTTTCTACGGGACAGTGGATGGA	47131
QY	1107	GTGACTTCAACA	ACACGCCCTTCCACTGGGAGAGGAAGTCTCGGTGTTTATAAACC	1166
Db	47132	GTGACTTCAACA	ACACGCCCTTCCACTGGGAGAGGAAGTCTCGGTGTTTATAAACC	47191
QY	1167	GAGGAGCAGTTG	ATTGTTGTTTATAAGGGAGAGATAACAATCTCTATATACACAACT	1226
Db	47192	GAGGAGCAGTTG	ATTGTTGTTTATAAGGGAGAGATAACAATCTCTATATACACAACT	47251
QY	1227	TCAAGGTTTGTG	AAACAATAGAACCTGTAAAGCAGGTGCCAGAACCTCAGGGCTGT	1286
Db	47252	TCAAGGTTTGTG	AAACAATAGAACCTGTAAAGCAGGTGCCAGAACCTCAGGGCTGT	47311
QY	1287	GTGTACTAATAC	AGACTATGTACCCCAATGCATATCAACATGTGTCAGGGAATATCC	1346
Db	47312	GTGTACTAATAC	AGACTATGTACCCCAATGCATATCAACATGTGTCAGGGAATATCC	47371
QY	1347	AGAAAACTGTGG	GATAGAGCTTTGACTCTCCAGAAAGCTCATCTCAGTCTCTGAAAAAT	1406
Db	47372	AGAAAACTGTGG	GATAGAGCTTTGACTCTCCAGAAAGCTCATCTCAGTCTCTGAAAAAT	47431
QY	1407	GCCTCATTTAC	CTTGCTTAATCCTTTTCTAGTCTTTCATATTTCTTCACTCAATCTC	1466
Db	47432	GCCTCATTTAC	CTTGCTTAATCCTTTTCTAGTCTTTCATATTTCTTCACTCAATCTC	47491
QY	1467	TGATTCTGCTCA	ATGCTTTGAAATCAAGGCCAGCTGGAGTGAAGAGAGAAATGTGACAG	1526
Db	47492	TGATTCTGCTCA	ATGCTTTGAAATCAAGGCCAGCTGGAGTGAAGAGAGAAATGTGACAG	47551
QY	1527	GCACAGATGAAT	GGGAGTGAGGATAGTGGGGTCAGGGCTGAGAGAGAGAGGAGAC	1586
Db	47552	GCACAGATGAAT	GGGAGTGAGGATAGTGGGGTCAGGGCTGAGAGAGAGAGGAGAC	47611
QY	1587	ATGAGCATGGCT	GAGCTTGACAAAAGCAAAAGGTGACAAAAGGCTCAGCATTTAGCCA	1646
Db	47612	ATGAGCATGGCT	GAGCTTGACAAAAGCAAAAGGTGACAAAAGGCTCAGCATTTAGCCA	47671
QY	1647	GGAGATCATACT	GGTCTTAGCCCCATCTGCCACAGTGTATTTAACTTGAAGGTTTCAAC	1706
Db	47672	GGAGATCATACT	GGTCTTAGCCCCATCTGCCACAGTGTATTTAACTTGAAGGTTTCAAC	47731
QY	1707	AGGTCAGGGAG	AGTTTGGAACTGCAATAACCTGGGAGTTTTGGTGGAGTCCGATGATTC	1766
Db	47732	AGGTCAGGGAG	AGTTTGGAACTGCAATAACCTGGGAGTTTTGGTGGAGTCCGATGATTC	47791
QY	1767	TCCTTTGTCAT	AGTGCATGACATTTTTTTCCTTTTATACAGTTTATCTATGCAACCCATG	1826

Db	47792	TCTTTTGCATTAAGTGCATGACATATTTTGTGCTTTATTACAGTTATCTATGCGACCCCATG	47851
Qy	1827	CACCTTACATTTGAAATCATGAAATATCATGCTCCCATGTTTCAGATGCTTCTTTAGGCCA	1886
Db	47852	CACCTTACATTTGAAATCATGAAATATCATGCTCCCATGTTTCAGATGCTTCTTTAGGCCA	47911
Qy	1887	CATCCCCCTGCTCAAAATTCAGAAAATTTTGGTTTATAAAAGATGCATTATCTATGATA	1946
Db	47912	CATCCCCCTGCTCAAAATTCAGAAAATTTTGGTTTATAAAAGATGCATTATCTATGATA	47971
Qy	1947	TGCTAAATATATGATATATGCAATATAAA	1973
Db	47972	TGCTAAATATATGATATATGCAATATAAA	47998

RESULT 3

RESULT 3
AAAF21272
ID AAAF21272 standard; DNA: 143068 BP.

AA
AC
AAF21272:

DT 14-MAR-2001 (first entry)

DE Human low adenosine antisense oligonucleotide related sequence #2839.

Low adenosine antisense oligonucleotide; phosphorothioate; allergy; human; airway disorder; bronchoconstriction; lung inflammation; surfactant depletion; respiratory; bronchodilator; antiinflammatory immunosuppressive; antasthmatic; analgesic; hypotensive; cytostatic; respiratory obstruction; pulmonary obstruction; impeded respiration; surfactant hypoproduction; pulmonary vasoconstriction; asthma; ROS; respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis; pulmonary hypertension; emphysema; pulmonary transplantation rejector; chronic obstructive pulmonary disease; pulmonary infection; bronchial cancer; ss.

OS Homo sapiens.

PN WO200062736-A2.

26-OCT-2000.

24-MAR-2000; 2000WO-US08020.

PR 06-APR-1999; 99US-0127958.

PA (UYEC-) UNIV EAST CAROLINA.

XX
(NICE/) NICE J W.

XX
NYCE JW;

DR
XX
WPT; 2000-6/9539/66.

Low adenosine (A) content antisense oligonucleotides which do not trigger adenosine receptors during metabolism, useful e.g. for treating cancers and respiratory obstructions -

PS Disclosure; Page 1186-1219; 1592pp; English;

The present invention describes low adenosine (A) content antisense oligonucleotides and compositions (I) comprising them. In the antisense oligonucleotides the A is replaced by a 'Universal' or alternative base. (I) can have respiratory, bronchodilator, antiinflammatory, analgesic, immunosuppressive, antiasthmatic, hypotensive and cytostatic activities. The antisense oligonucleotides and (I) can be used to down-regulate the expression and or activity of target polypeptides associated with lung/respiratory disorders and malignancies, such as stimulating and activating peptide factors and transmitters, transcription factors, immunoglobulins and antibodies, antibody receptors, cytokines and chemokines, endogenously produced specific and non-specific enzymes, binding proteins, adhesion molecules and their receptors, cytokine and chemokine receptors, adenosine receptors, bradykinin receptors, central nervous system (CNS) and peripheral nervous and non-nervous system

Db 46772 TCGGGAATCCTGAAAAACCCCTGCTTCGGTGTCTGGAACGAGAGGCATATAGGGCAGTG 46833

QY 1887 CATCCCTCTCTAAATTCAGAAATTTGTTTATATAAAGATGCAATATCTATGATA 1946
|||||
Db 47912 CATCCCTCTCTAAATTCAGAAATTTGTTTATATAAAGATGCAATATCTATGATA 47971
|||||
QY 1947 TGCTAATATATGATATGCAATATAA 1973
|||||
Db 47972 TGCTAATATATGATATGCAATATAA 47998
|||||

RESULT 4

AAA34983

ID AAA34983 standard; DNA; 143068 BP.

XX

AC AAA34983;

XX

DT 28-JUL-2000 (first entry)

XX

DE

XX

XX

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

Human adenosine receptor related polynucleotide SEQ ID NO:2672.

Human: adenosine receptor; low adenosine antisense oligonucleotide;
phosphorothioate; impaired respiration; inflammation; allergy;
allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
antiallergic; antiasthmatic; cytosolic; analgesic; impaired airway;
lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
respiratory distress syndrome; pain; cystic fibrosis; emphysema;
pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.

Homo sapiens.

OS

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

New antisense oligonucleotides useful for treating e.g. pulmonary
vasoconstriction, inflammation, allergies, asthma, hypertension,
bronchitis, emphysema, respiratory distress syndrome, ischemia or
cancers -

Disclosure; Page 851-882; 1343pp; English.

The present invention describes a new composition comprising an
antisense oligonucleotide (ON) with low adenosine (up to 15%), which
targets nucleic acids involved in bronchoconstriction, allergies, and/or
inflammation. The ON can have antiinflammatory, antiallergic,
antiasthmatic, cytosolic and analgesic activities. The compositions are
useful for the treatment of diseases associated with inflammation,
impaired airways, including lung disease and diseases whose secondary
effects afflict the lungs of a subject. They can be used for treating
e.g. ischaemic conditions, pulmonary vasoconstriction, allergies,
asthma, impaired respiration, respiratory distress syndrome, pain, cystic
fibrosis, pulmonary hypertension, emphysema, chronic obstructive
pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
carcinomas, and cancers which may metastasize to the lungs, including
breast and prostate cancer. The reduction of the adenosine content of
the ONs reduces side effects. The A-containing ONs break down with the
release of deoxyadenosine which activates adenosine receptors causing
bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
nucleotide sequences given in the sequence listing from the present
invention, which correspond to SEQ ID NO:1 to 2815, and then the last
185 sequences are also called SEQ ID NO:1 to 185, but the sequences
differ from the previously named sequences. SEQ ID NO:11 to 1680
(AAA32323 to AAA33992) are specifically claimed ONs from the present

[illegible]


```
Db 46052 CAGAACAGAGAAAGTGATTGACAAAGGACGCAATTTCCCCAGTACATCCACACATGCTG 46111
QY 87 TCCACATCTGTTCTCGGTTTATCAGAAATACCAAGAGAGCGGTGAAGAAGTCACCAAC 146
Db 46112 TCCACATCTGTTCTCGGTTTATCAGAAATACCAAGAGAGCGGTGAAGAAGTCACCAAC 46171
QY 147 TTTTGTGATTATGATTACGGTCTCCCTGTCATATAATTTGAGCTGAAGCAAAATTTGGGGCC 206
Db 46172 TTTTGTGATTATGATTACGGTCTCCCTGTCATATAATTTGAGCTGAAGCAAAATTTGGGGCC 46231
QY 207 CAATCTCTGCTCGCTCTACTCGTGTGTTTCATCTTTTGTGTTTGTGGGCAACATGCTG 266
Db 46232 CAATCTCTGCTCGCTCTACTCGTGTGTTTCATCTTTTGTGTTTGTGGGCAACATGCTG 46291
QY 267 GTGCTCTCATCTTTAATAAAGCTGAAAGCTGAAGTCTTGACGTGACATTTACCTGCTC 326
Db 46292 GTGCTCTCATCTTTAATAAAGCTGAAAGCTGAAGTCTTGACGTGACATTTACCTGCTC 46351
QY 327 AACCTGGCCATCTCTGATCTGCTTTTCTTATTACTCTCCCAATGCTGCAATTTACCTGCT 386
Db 46352 AACCTGGCCATCTCTGATCTGCTTTTCTTATTACTCTCCCAATGCTGCAATTTACCTGCT 46411
QY 387 GCAATGAGTGGTCTTTTGGGAATGCAATGTGCAAAATTAATTCACAGGCTGTATCACATC 446
Db 46412 GCAATGAGTGGTCTTTTGGGAATGCAATGTGCAAAATTAATTCACAGGCTGTATCACATC 46471
QY 447 GGTATTTTGGCGGAATCTTCTTCATCATCTCTCTGACATCGATGATAGATACCTGGCTATT 506
Db 46472 GGTATTTTGGCGGAATCTTCTTCATCATCTCTCTGACATCGATGATAGATACCTGGCTATT 46531
QY 507 GTCATGCTGTGTTTGTAAAGCCAGGACGCTACCTTTGGGGTGGTGACAAAGTGTG 566
Db 46532 GTCATGCTGTGTTTGTAAAGCCAGGACGCTACCTTTGGGGTGGTGACAAAGTGTG 46591
QY 567 ATCACCTGTTGTTGCTGTTGCTTCTGTCGCCAGGATCACTTTTACTTAATGCTGAC 626
Db 46592 ATCACCTGTTGTTGCTGTTGCTTCTGTCGCCAGGATCACTTTTACTTAATGCTGAC 6651
QY 627 AAGAAGATCTGTTTATGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 746
Db 46652 AAGAAGATCTGTTTATGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 46711
QY 687 ACAATAATCAGAACATTTTGGGCTGGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 746
Db 46712 ACAATAATCAGAACATTTTGGGCTGGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 46771
QY 747 TCGGAATCTCTGAAACCCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 806
Db 46772 TCGGAATCTCTGAAACCCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 866
QY 807 AGAGTCATCTTCCATCATGATTTGTTTACTTTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 866
Db 46832 AGAGTCATCTTCCATCATGATTTGTTTACTTTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 46891
QY 867 ATCTCTCTGAAACCTCTCCAGGAATCTTCCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 926
Db 46892 ATCTCTCTGAAACCTCTCCAGGAATCTTCCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 46951
QY 927 CTGACCAAGCCAGCAGGTGACAGAGACTCTTGGGATGACACTGCTGCTGCTGCTGCTGCTGCTGCTGCT 986
Db 46952 CTGACCAAGCCAGCAGGTGACAGAGACTCTTGGGATGACACTGCTGCTGCTGCTGCTGCTGCTGCTGCT 47011
QY 987 ATCATCTATGCTTCTGTTGGGAGAAAGTTCAGAGGTATCTCTCGGTGCTGCTGCTGCTGCTGCTGCTGCT 1046
Db 47012 ATCATCTATGCTTCTGTTGGGAGAAAGTTCAGAGGTATCTCTCGGTGCTGCTGCTGCTGCTGCTGCTGCT 47071
QY 1047 CACATCACCAGCGCTTCTGCAAAACATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1106
Db 47072 CACATCACCAGCGCTTCTGCAAAACATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 47131
QY 1107 GTGACTTCAACAAACAGCGCTTCCACTGGGAGCAGGAAGTCTCGGCTGGTGTATTAAC 1166
Db 47132 GTGACTTCAACAAACAGCGCTTCCACTGGGAGCAGGAAGTCTCGGCTGGTGTATTAAC 47191
```

RESULT 6

ABL68124

ID ABL68124 standard; DNA; 143068 BP.

XX ABL68124;

XX ABL68124;

DT 15-MAY-2002 (first entry)

XX Ovary cancer related gene sequence SEQ ID NO:6461.

DE Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;

KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;

KW cytostatic; gene therapy; antineoplastic; Wilms' tumour; adenocarcinoma; gene; ds.

OS Homo sapiens.

XX W0200194629-A2.

XX 13-DEC-2001.

XX 30-MAY-2001; 2001WO-US10838.

XX 05-JUN-2000; 2000US-209473P.

XX 05-JUN-2000; 2000US-209531P.

XX 18-SEP-2000; 2000US-233133P.

XX 18-SEP-2000; 2000US-233617P.

XX 20-SEP-2000; 2000US-234009P.

XX 20-SEP-2000; 2000US-234034P.

XX 20-SEP-2000; 2000US-234052P.

XX 22-SEP-2000; 2000US-234509P.

XX 22-SEP-2000; 2000US-234567P.

XX 25-SEP-2000; 2000US-234923P.

XX 25-SEP-2000; 2000US-234924P.

XX 25-SEP-2000; 2000US-235077P.

XX 25-SEP-2000; 2000US-235082P.

XX 25-SEP-2000; 2000US-235134P.

XX 25-SEP-2000; 2000US-235280P.

XX 26-SEP-2000; 2000US-235637P.

XX 26-SEP-2000; 2000US-235638P.

XX 27-SEP-2000; 2000US-235711P.

XX 27-SEP-2000; 2000US-235720P.

XX 27-SEP-2000; 2000US-235840P.

XX 27-SEP-2000; 2000US-235863P.

XX 28-SEP-2000; 2000US-236028P.

XX 28-SEP-2000; 2000US-236032P.

XX 28-SEP-2000; 2000US-236033P.

XX 28-SEP-2000; 2000US-236034P.

XX 28-SEP-2000; 2000US-236109P.

XX 28-SEP-2000; 2000US-236111P.

XX 29-SEP-2000; 2000US-236842P.

XX 29-SEP-2000; 2000US-236891P.

XX 02-OCT-2000; 2000US-237172P.

XX 02-OCT-2000; 2000US-237173P.

XX 02-OCT-2000; 2000US-237278P.

XX 02-OCT-2000; 2000US-237294P.

XX 02-OCT-2000; 2000US-237295P.

XX 02-OCT-2000; 2000US-237316P.

XX 03-OCT-2000; 2000US-237425P.

XX 03-OCT-2000; 2000US-237598P.

XX 03-OCT-2000; 2000US-237604P.

XX 03-OCT-2000; 2000US-237606P.

XX 03-OCT-2000; 2000US-237608P.

XX 01-NOV-2000; 2000US-244867P.

XX 01-NOV-2000; 2000US-245084P.

XX (AVAL-) ANVALON PHARM.

XX Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrihan S;

XX Soppet DR, Weaver Z;

XX WPI; 2002-188264/24.

XX Screening for anti-neoplastic agent involves exposing cells to a

XX chemical agent to be tested for anti-neoplastic activity, and

XX determining a change in expression of a gene of a signature gene set

XX Claim 1; SEQ ID 6461; 44pp; English.

XX The present invention describes a method (M1) for screening for an

XX anti-neoplastic agent. The method involves exposing cells to a chemical

XX agent to be tested for anti-neoplastic activity, determining a change in

XX expression of at least one gene (I) of a signature gene set, where (I)

XX comprises a sequence (S) selected from 8447 sequences (given in ABL61664

XX to ABL70110), or is at least 95% identical to (S), where a change in

XX expression is indicative of anti-neoplastic activity. (I) has cytostatic

XX activity and can be used in gene therapy. M1 can be used for screening

XX an anti-neoplastic agent, and can be used for producing a product which

is the data collected with respect to the anti-neoplastic agent as a result of M1, and the data is sufficient to convey the chemical structure and/or properties of the agent. M1 can be used in the treatment of cancer such as colon, breast, stomach, lung, thyroid, oesophageal, ovarian, kidney, prostate or pancreatic cancer, adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer, infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine carcinoma, papillary carcinoma and Wilms' tumour.

Sequence 143068 BP; 41194 A; 30122 C; 32403 G; 39349 T; 0 other;

Query Match 98.2%; Score 1943.8; DB 24; Length 143068;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 1945; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 27 CTGAACAGAGAAAGTGGATTGAACAAGGACGCAATTTCCCCAGTACATCCACACATGCTG 86
DB 46052 CAGAACAGAGAAAGTGGATTGAACAAGGACGCAATTTCCCCAGTACATCCACACATGCTG 46111
QY 87 TCCACATCTCGTTCTCGGTTTATCAGAAATACCAACGAGAGCGGTGAAGAAGTCACACC 146
DB 46112 TCCACATCTCGTTCTCGGTTTATCAGAAATACCAACGAGAGCGGTGAAGAAGTCACACC 46171
QY 147 TTTTGTGATTATGATTACGGTCTCCCTGTCATAAATTTGACGTGAAGCAAAATGGGGCC 206
DB 46172 TTTTGTGATTATGATTACGGTCTCCCTGTCATAAATTTGACGTGAAGCAAAATGGGGCC 46231
QY 207 CAATCTCGCTCCGCTCTACTCGTGGTTCATCTTTGTTTGGTGGCAACATGCTG 266
DB 46232 CAATCTCGCTCCGCTCTACTCGTGGTTCATCTTTGTTTGGTGGCAACATGCTG 46291
QY 267 GTCGCTCTCATCTTAATAAAGCTGCAAAAGCTGAAGTGTGACTGACATTTACCTGCTC 326
DB 46292 GTCGCTCTCATCTTAATAAAGCTGCAAAAGCTGAAGTGTGACTGACATTTACCTGCTC 46351
QY 327 AACCTGGCCATCTCTGATCTGTTTTCTTATTACTCTCCCATTTGGGCTCACTGCT 386
DB 46352 AACCTGGCCATCTCTGATCTGTTTTCTTATTACTCTCCCATTTGGGCTCACTGCT 46411
QY 387 GCAAAATGAGTGGTCTTTGGGAATGCAATGTGCAAAATTTACACAGGCTGTATCACATC 446
DB 46412 GCAAAATGAGTGGTCTTTGGGAATGCAATGTGCAAAATTTACACAGGCTGTATCACATC 46471
QY 447 GGTATTTTGGCGGAATCTTTCATCATCCTCTGACAAATGATAGATACCTGGCTATT 506
DB 46472 GGTATTTTGGCGGAATCTTTCATCATCCTCTGACAAATGATAGATACCTGGCTATT 46531
QY 507 GTCCATGCTGTGTTGCTTTAAAGCCAGGACGCTACCTTTGGGGTGTGACAAGTGTG 566
DB 46532 GTCCATGCTGTGTTGCTTTAAAGCCAGGACGCTACCTTTGGGGTGTGACAAGTGTG 46591
QY 567 ATCACCCTGGTGGTGGTCTGTTTGTCTGTCGCCAGGAATCATCTTTACTAAATGCCAG 626
DB 46592 ATCACCCTGGTGGTGGTCTGTTTGTCTGTCGCCAGGAATCATCTTTACTAAATGCCAG 46651
QY 627 AAAGAAGATTTCTGTTTAAGTCTGTGGCCCTTATTTCCAGGAGGATGAATAATTTCCAC 686
DB 46652 AAAGAAGATTTCTGTTTAAGTCTGTGGCCCTTATTTCCAGGAGGATGAATAATTTCCAC 46711
QY 687 ACAATAATGAGGACATTTTGGGCTGTCTGCGCTGCTCATCTGCTCATCTGCTGCTAC 746
DB 46712 ACAATAATGAGGACATTTTGGGCTGTCTGCGCTGCTCATCTGCTCATCTGCTGCTAC 46771
QY 747 TCGGGAATCTCTGAAACCCCTGCTTGGTGTGCGAAACGAGAGAGAGGATAGGGCAGTG 806
DB 46772 TCGGGAATCTCTGAAACCCCTGCTTGGTGTGCGAAACGAGAGAGAGGATAGGGCAGTG 46831
QY 807 AGAGTCACTTCCACCATCATGATTGTTTACTTCTTCTGAGACTCCCTATAACATGCTC 866
DB 46832 AGAGTCACTTCCACCATCATGATTGTTTACTTCTTCTGAGACTCCCTATAACATGCTC 46891
QY 867 ATTCTCTGACACCTTCCAGGAATCTTGGGCTGTGAGTAACTGTGAAAGCAGCAGTCAA 926
|||||

Db 46892 ATTCTCTGACACCTTCCAGGAATCTTGGCCCTGAGTAACTGTGAAGACCAGTCAA 46951
QY 927 CTGGACCAAGCCAGCGAGGTGACAGAGACTTTGGGATGACTCACTGCTGCATCAATCCC 986
Db 46952 CTGGACCAAGCCAGCGAGGTGACAGAGACTTTGGGATGACTCACTGCTGCATCAATCCC 47011
QY 987 ATCATCTATGCTTCTGTTGGGAGAGTTTCCAGAGGTATCTCTCGGTGTTCTCCGAAAG 1046
Db 47012 ATCATCTATGCTTCTGTTGGGAGAGTTTCCAGAGGTATCTCTCGGTGTTCTCCGAAAG 47071
QY 1047 CACATCACCAGCGCTTCTGCAACAAATGTCAGTTTTCACAGGGAGACAGTGGATGGA 1106
Db 47072 CACATCACCAGCGCTTCTGCAACAAATGTCAGTTTTCACAGGGAGACAGTGGATGGA 47131
QY 1107 GTGACTTCAACAAACAGCGCTTCCACTGGGAGCAGGAAGTCTCGGCTGTTTATAAAG 1166
Db 47132 GTGACTTCAACAAACAGCGCTTCCACTGGGAGCAGGAAGTCTCGGCTGTTTATAAAG 47191
QY 1167 GAGGACAGTTTGAATGTTTATTAAGAGGAGATACAAATCTGTATATAACAACAAT 1226
Db 47192 GAGGACAGTTTGAATGTTTATTAAGAGGAGATACAAATCTGTATATAACAACAAT 47251
QY 1227 TCAAGGGTTGTTGAACAAATAGAAACCTGTAAAGCAGGTGCCAGGAACCTCAGGGCTGT 1286
Db 47252 TCAAGGGTTGTTGAACAAATAGAAACCTGTAAAGCAGGTGCCAGGAACCTCAGGGCTGT 47311
QY 1287 GTGTACTATACAGACTATGTACCAACATGCATATCCACATGTGCTCAGGGAATATCC 1346
Db 47312 GTGTACTATACAGACTATGTACCAACATGCATATCCACATGTGCTCAGGGAATATCC 47371
QY 1347 AGAAAACTGTGGGTAGAGACTTTGACTCTCCAGAAAGTCTACTCAGCTCCTGAAAT 1406
Db 47372 AGAAAACTGTGGGTAGAGACTTTGACTCTCCAGAAAGTCTACTCAGCTCCTGAAAT 47431
QY 1407 GCCTCATTAACCTTGCTTAATCCTCTTTTCTAGTCTTCAATATTTCTTCACTCAATCTC 1466
Db 47432 GCCTCATTAACCTTGCTTAATCCTCTTTTCTAGTCTTCAATATTTCTTCACTCAATCTC 47491
QY 1467 TGATCTGTCATGCTTGAATCAAGGCCAGCTGGAGGTGAAGAGAAATGTGACAG 1526
Db 47492 TGATCTGTCATGCTTGAATCAAGGCCAGCTGGAGGTGAAGAGAAATGTGACAG 47551
QY 1527 GCACAGATGAATGGGAGTGAGGATAGTGGGTGAGGCTGAGAGAGAGAGGAGAC 1586
Db 47552 GCACAGATGAATGGGAGTGAGGATAGTGGGTGAGGCTGAGAGAGAGAGGAGAC 47611
QY 1587 ATGAGCATGGCTGAGCCTGGACAAAGAGAGGTGAGCAAGGGCTCAGGCATTCAGCCA 1646
Db 47612 ATGAGCATGGCTGAGCCTGGACAAAGAGAGGTGAGCAAGGGCTCAGGCATTCAGCCA 47671
QY 1647 GGAGATGATGCTGCTTACCCCATCTGCCAGTGTATTTAACTTGAAGGGTTCACC 1706
Db 47672 GGAGATGATGCTGCTTACCCCATCTGCCAGTGTATTTAACTTGAAGGGTTCACC 47731
QY 1707 AGGTGAGGAGAGTTTGGGAATGCAATATCACTGGAGCTTGGAGTCCGATGATTC 1766
Db 47732 AGGTGAGGAGAGTTTGGGAATGCAATATCACTGGAGCTTGGAGTCCGATGATTC 47791
QY 1767 TCTTTTCATAGTCATGACATATTTTGTGTTTATACAGTTTATCATGATGATTC 1826
Db 47792 TCTTTTCATAGTCATGACATATTTTGTGTTTATACAGTTTATCATGATGATTC 47851
QY 1827 CACCTTACATTTGAAATCTATGAATATCATGCTCCATGTTTCAGATGCTTTCAGGCCA 1886
Db 47852 CACCTTACATTTGAAATCTATGAATATCATGCTCCATGTTTCAGATGCTTTCAGGCCA 47911
QY 1887 CATCCCTGCTCAAAATTCAGAAAATTTTGTGTTTATAAGATGCAATATCATGATA 1946
Db 47912 CATCCCTGCTCAAAATTCAGAAAATTTTGTGTTTATAAGATGCAATATCATGATA 47971
QY 1947 TGCTATATATGATGATGCAATATAA 1973
Db 47972 TGCTATATATGATGATGCAATATAA 47998

RESULT 7

AAA35151

ID AAA35151 standard; DNA; 149412 BP.

XX AAA35151;

XX 28-JUL-2000 (first entry)

XX Human adenosine receptor related polynucleotide 2nd SEQ ID NO:25.

XX Human; adenosine receptor; low adenosine antisense oligonucleotide;
phosphorothioate; impaired respiration; inflammation; allergy;
allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
antiallergic; anasthmatic; cytotatic; analgesic; impaired airway;
lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
respiratory distress syndrome; pain; cystic fibrosis; emphysema;
pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.

XX Homo sapiens.

XX WO200009525-A2.

XX 24-FEB-2000.

XX 03-AUG-1999; 99WO-US17712.

XX 03-AUG-1998; 98US-0095212.

XX (UYEC-) UNIV EAST CAROLINA.

XX Nyce JW;

XX WPI; 2000-205971/18.

XX New antisense oligonucleotides useful for treating e.g. pulmonary
PT vasoconstriction, inflammation, allergies, asthma, hypertension, or
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT cancers

XX Disclosure; Page 1138-1171; 1343pp; English.

XX The present invention describes a new composition comprising an
CC antisense oligonucleotide (ON) with low adenosine (up to 15%), which
CC targets nucleic acids involved in bronchoconstriction, allergies, and/or
CC inflammation. The ON can have antiinflammatory, antiallergic,
CC antiasthmatic, cytostatic and analgesic activities. The compositions are
CC useful for the treatment of diseases associated with inflammation,
CC impaired airways, including lung disease and diseases whose secondary
CC effects afflict the lungs of a subject. They can be used for treating
CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies,
CC asthma, impaired respiration, respiratory distress syndrome, pain, cystic
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
CC carcinomas, and cancers which may metastasize to the lungs, including
CC the breast and prostate cancer. The reduction of the adenosine content of
CC the ONs reduces side effects. The A-containing ONs break down with the
CC release of deoxyadenosine which activates adenosine receptors causing
CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
CC nucleotide sequences given in the sequence listing from the present
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
CC differ from the previously named sequences. SEQ ID NO:11 to 180
CC (AAA32323 to AAA33992) are specifically claimed ONs from the present
CC invention. N.B. Sequences given in the disclosure of the present
CC invention do not match up with their corresponding SEQ ID NO: sequences
CC given in the sequence listing.

XX SQ Sequence 149412 BP; 43049 A; 31388 C; 33852 G; 41123 T; 0 other;

XX Query Match 98.2%; Score 1943.8; DB 21; Length 149412;

Best Local Similarity 99.9%; Pred. No. 0; Mismatches 0; Indels 0; Gaps 0;									
Matches 1945; Conservative 0;									
QY	27	CTGAACAGAGAAAGTGGATTGAACAGAGAGCGCATTTCCCCAGTACATCCACACATGCTG	86						
Db	52396	CAGAACAGAGAAAGTGGATTGAACAGAGAGCGCATTTCCCCAGTACATCCACACATGCTG	52455						
QY	87	TCACATCTCGTCTCGGTTTATCAGAAATACCAGAGAGCGGTGAAGATCACCAC	146						
Db	52456	TCACATCTCGTCTCGGTTTATCAGAAATACCAGAGAGCGGTGAAGATCACCAC	52515						
QY	147	TTTTTTGATTATGATTACGGTGTCCCTGTCATAAATTTGACGTGAAGCAAAATTTGGGGC	206						
Db	52516	TTTTTTGATTATGATTACGGTGTCCCTGTCATAAATTTGACGTGAAGCAAAATTTGGGGC	52575						
QY	207	CAACTCCGCTCCGCTCTACTCGCTGGTTCATCTTTGGTTTGGGCAACATGCTG	266						
Db	52576	CAACTCCGCTCCGCTCTACTCGCTGGTTCATCTTTGGTTTGGGCAACATGCTG	52635						
QY	267	GTGCTCTCATCTTAATAACTGCAAAAGCTGAAGTGTGACTGACATTTACCTGCTC	326						
Db	52636	GTGCTCTCATCTTAATAACTGCAAAAGCTGAAGTGTGACTGACATTTACCTGCTC	52695						
QY	327	AACCTGGCCATCTCTGATCTGCTTTTCTATTACTCTCCCATTTGGGCTCACTCTGCT	386						
Db	52696	AACCTGGCCATCTCTGATCTGCTTTTCTATTACTCTCCCATTTGGGCTCACTCTGCT	52755						
QY	387	GCAAAATGAGTGGGTCTTTGGGAATGCAATGTGCAAAATTTATCAGAGGCTGTATCATT	446						
Db	52756	GCAAAATGAGTGGGTCTTTGGGAATGCAATGTGCAAAATTTATCAGAGGCTGTATCATT	52815						
QY	447	GGTTATTTTGGCGGAATCTTCTTCATCATCTCTGCAATCGATAGATACCTGGCTATT	506						
Db	52816	GGTTATTTTGGCGGAATCTTCTTCATCATCTCTGCAATCGATAGATACCTGGCTATT	52875						
QY	507	GTCCATCTGTGTTGCTTTAAAGCCAGGACGGTCACTTTGGGCTGGTGACAAGTGTG	566						
Db	52876	GTCCATCTGTGTTGCTTTAAAGCCAGGACGGTCACTTTGGGCTGGTGACAAGTGTG	52935						
QY	567	ATCACCTGGTGGGTGTGTTTGGTCTGTGCCAGGAATCATCTTTACTAAATGCCAG	626						
Db	52936	ATCACCTGGTGGGTGTGTTTGGTCTGTGCCAGGAATCATCTTTACTAAATGCCAG	52995						
QY	627	AAAGAAATCTGTGTTATGCTGTGGCCCTTATTTTCCAGAGGATGGAATTTCCAC	686						
Db	52996	AAAGAAATCTGTGTTATGCTGTGGCCCTTATTTTCCAGAGGATGGAATTTCCAC	53055						
QY	687	ACAATAATGAGGAACATTTTGGGCTGTCTGCTGCTGCTCATCTGTCATCTGCTAC	746						
Db	53056	ACAATAATGAGGAACATTTTGGGCTGTCTGCTGCTGCTCATCTGTCATCTGCTAC	53115						
QY	747	TCGGGAATCTGAAACCCCTGCTTCGGTGTGCAACAGAGAGAGAGGCGCATAGGCGATG	806						
Db	53116	TCGGGAATCTGAAACCCCTGCTTCGGTGTGCAACAGAGAGAGAGGCGCATAGGCGATG	53175						
QY	807	AGAGTCATCTTCACATCATGATGTTTACTTTCTCTCTGCTGCTGCTATTAACATTTGC	866						
Db	53176	AGAGTCATCTTCACATCATGATGTTTACTTTCTCTCTGCTGCTGCTATTAACATTTGC	53235						
QY	867	ATTCCTCTGAACACCTTCCAGGAATTCCTGGCCCTGAGTAATCTGTGAAGCACCAGTCAA	926						
Db	53236	ATTCCTCTGAACACCTTCCAGGAATTCCTGGCCCTGAGTAATCTGTGAAGCACCAGTCAA	53295						
QY	927	CTGACCAAGCCAGCGAGTACAGAGACTCTTGGGATGACTCACTGCTGATCAATCCC	986						
Db	53296	CTGACCAAGCCAGCGAGTACAGAGACTCTTGGGATGACTCACTGCTGATCAATCCC	53355						
QY	987	ATCATCTATGCTTCTGTTGGGAGAAATTCAGAGGATATCTCTCGGTGTTCTCCGAAG	1046						
Db	53356	ATCATCTATGCTTCTGTTGGGAGAAATTCAGAGGATATCTCTCGGTGTTCTCCGAAG	53415						
QY	1047	CACATCACCAAGCGGCTCTGCAAAACAAATGTCCAGTTTTTCTACAGGGAGACAGTGGATGA	1106						

RESULT 8

AAF21273 standard; DNA; 152740 BP.

AAF21273;

14-MAR-2001 (first entry)

Human low adenosine antisense oligonucleotide related sequence #2840.

Low adenosine antisense oligonucleotide; phosphorothioate; allergy; human; airway disorder; bronchoconstriction; lung inflammation; surfactant depletion; respiratory; bronchodilator; antiinflammatory; immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic; respiratory obstruction; pulmonary obstruction; impeded respiration; surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS; respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis; pulmonary hypertension; emphysema; pulmonary transplantation rejection; chronic obstructive pulmonary disease; pulmonary infection; bronchitis; cancer; ss.

Homo sapiens.

WO200062736-A2.

26-OCT-2000.

24-MAR-2000; 2000WO-US08020.

06-APR-1999; 99US-0127958.

(UYEC-) UNIV EAST CAROLINA.

(NYCE/) NYCE J W.

NYCE JW;

WPI; 2000-679539/66.

Low adenosine (A) content antisense oligonucleotides which do not trigger adenosine receptors during metabolism, useful e.g. for treating cancers and respiratory obstructions -

Disclosure; Page 1219-1254; 1592pp; English.

The present invention describes low adenosine (A) content antisense oligonucleotides and compositions (I) comprising them. In the antisense oligonucleotides the A is replaced by a 'Universal' or alternative base. (I) can have respiratory, bronchodilator, antiinflammatory, analgesic, immunosuppressive, antiasthmatic, hypotensive and cytostatic activities. The antisense oligonucleotides and (I) can be used to down-regulate the expression and/or activity of target polypeptides associated with lung/respiratory disorders and malignancies, such as stimulating and activating peptide factors and transmitters, transcription factors, immunoglobulins and antibodies, antibody receptors, cytokines and chemokines, endogenously produced specific and non-specific enzymes, binding proteins, adhesion molecules and their receptors, cytokine and chemokine receptors, adenosine receptors, bradykinin receptors, central nervous system (CNS) and peripheral nervous and non-nervous system transmitters, defensins, growth factors, vasoactive peptides and receptors, binding proteins and malignancy associated proteins. The antisense oligonucleotides may be used in this way to treat disorders including respiratory obstruction (especially pulmonary obstruction and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or surfactant hypoproduction which are associated with a disease or condition selected from pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary hypertension, emphysema, chronic obstructive pulmonary disease (COPD), pulmonary transplantation rejection, pulmonary infections, bronchitis, and/or cancer. AAF18434 to AAF21543 represent human polynucleotide fragments and antisense oligonucleotides used in the exemplification of the present invention.

Sequence 152740 BP; 44169 A; 32023 C; 34549 G; 41999 T; 0 other;

Query Match 98.2%; Score 1943.8; DB 21; Length 152740;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 1945; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 27 CTGACAGAGAAAGTGATGAACAAGAGCGCATTTCCCGAGTACATCCACAACATGCTG 86
Db 52396 CAGAACAGAGAAAGTGATGAACAAGAGCGCATTTCCCGAGTACATCCACAACATGCTG 52455

QY	87	TCCACATCTCGTTCTCGGTTTATCAGAAATACCAACGAGCGGTGAAGAGTCACAC	146
Db	52456	TCCACATCTCGTTCTCGGTTTATCAGAAATACCAACGAGCGGTGAAGAGTCACAC	52515
QY	147	TTTTTGTATTGATGATGAGGCTCCCTGTCATATAATTTGAGTGAAGCAAAATGGGGCC	206
Db	52516	TTTTTGTATTGATGATGAGGCTCCCTGTCATATAATTTGAGTGAAGCAAAATGGGGCC	52575
QY	207	CAACTCCGCTCCGCTCTACTCGCTGGTGTTCATCTTTGGTGTGGGCAACATGCTG	266
Db	52576	CAACTCCGCTCCGCTCTACTCGCTGGTGTTCATCTTTGGTGTGGGCAACATGCTG	52635
QY	267	GTCGTCTCATCTTAATAAACTGCAAAAAGCTGAAGTGTCTGACATGACATTTACCTGCTC	326
Db	52636	GTCGTCTCATCTTAATAAACTGCAAAAAGCTGAAGTGTCTGACATGACATTTACCTGCTC	52695
QY	327	AACCTGGCCATCTCTGATCTGCTTTTCTTATTAATCTCTCCCATTTGGGCTCACTCTGCT	386
Db	52696	AACCTGGCCATCTCTGATCTGCTTTTCTTATTAATCTCTCCCATTTGGGCTCACTCTGCT	52755
QY	387	GCAAAATGAGTGGGCTTTGGGAATGCAATGCAATGCAATGCAATGCAATGCAATGCAATG	446
Db	52756	GCAAAATGAGTGGGCTTTGGGAATGCAATGCAATGCAATGCAATGCAATGCAATGCAATG	52815
QY	447	GGTTATTTTGGCGGAATCTTCTTCATCATCTCTCTGCAATGCAATGCAATGCAATGCAATG	506
Db	52816	GGTTATTTTGGCGGAATCTTCTTCATCATCTCTCTGCAATGCAATGCAATGCAATGCAATG	52875
QY	507	GTCATCTGCTGTTGTTGTTTAAAGCCAGGAGGCTGACCTTTTGGGCTGGTGAAGTGTG	566
Db	52876	GTCATCTGCTGTTGTTGTTTAAAGCCAGGAGGCTGACCTTTTGGGCTGGTGAAGTGTG	52935
QY	567	ATCACCTGGTGGGCTGCTTTGCTCTCTCCAGCAATCATCTTTACTTAATGCCAG	626
Db	52936	ATCACCTGGTGGGCTGCTTTGCTCTCTCCAGCAATCATCTTTACTTAATGCCAG	52995
QY	627	AAAGAAGATTCTGTTTATGCTGTGGGCTTATTTTCCACGAGGATGAATAATTTCCAC	686
Db	52996	AAAGAAGATTCTGTTTATGCTGTGGGCTTATTTTCCACGAGGATGAATAATTTCCAC	53055
QY	687	ACATAATGAGGAACATTTTGGGCTGGTCTCGGCTGCTCATCATGGTCAATGCTGAC	746
Db	53056	ACATAATGAGGAACATTTTGGGCTGGTCTCGGCTGCTCATCATGGTCAATGCTGAC	53115
QY	747	TCGGGAATCTGAAAAACCCCTGCTTCGGTGTGCAAAACGAGAGAGAGCATAGGCGAGT	806
Db	53116	TCGGGAATCTGAAAAACCCCTGCTTCGGTGTGCAAAACGAGAGAGAGCATAGGCGAGT	53175
QY	807	AGAGTCAATCTTCCATCATGATGTTTACTTTCTTCTGCTGCTCCCTATAACATTTGTC	866
Db	53176	AGAGTCAATCTTCCATCATGATGTTTACTTTCTTCTGCTGCTCCCTATAACATTTGTC	53235
QY	867	ATTCTCTGAACACCTTCCAGGATTTCTGGGCTGAGTAATCTGGAAGCAGCATGCA	926
Db	53236	ATTCTCTGAACACCTTCCAGGATTTCTGGGCTGAGTAATCTGGAAGCAGCATGCA	53295
QY	927	CTGGACCAAGCCACGAGGTGACAGAGACTCTTGGGATGACTCACTGCTGATCAATCCC	986
Db	53296	CTGGACCAAGCCACGAGGTGACAGAGACTCTTGGGATGACTCACTGCTGATCAATCCC	53355
QY	987	ATCATCTATGCTTCTGTTGGGAGAGTTTCAGAAAGTATCTCTCGGTGTTCTTCGGAAG	1046
Db	53356	ATCATCTATGCTTCTGTTGGGAGAGTTTCAGAAAGTATCTCTCGGTGTTCTTCGGAAG	53415
QY	1047	CACATCAACCAAGCGCTTCTGCAACAAATGTCAGATTTCTTACAGGGAGACAGTGGATGA	1106
Db	53416	CACATCAACCAAGCGCTTCTGCAACAAATGTCAGATTTCTTACAGGGAGACAGTGGATGA	53475
QY	1107	GTGACTTCAACAAACAGCGCTTCCACTGGGAGCAGGAAGTCTCGGCTGGTTTATAAACC	1166
Db	53476	GTGACTTCAACAAACAGCGCTTCCACTGGGAGCAGGAAGTCTCGGCTGGTTTATAAACC	53535

QY 1167 GAGGAGCAGTTGATTTGTTTATTAAGGGAGATACAACTCTGTATATATAACAACAACCT 1226
Db 53536 GAGGAGCAGTTGATTTGTTTATTAAGGGAGATACAACTCTGTATATATAACAACAACCT 53595
QY 1227 TCAAGGGTTTGTGAACATAGAACTCTTAAGCAGGTGCGCCAGGAACCTCAGGGCTGT 1286
Db 53596 TCAAGGGTTTGTGAACATAGAACTCTTAAGCAGGTGCGCCAGGAACCTCAGGGCTGT 53655
QY 1287 GTGTACTAATACAGACTATGTCAACCAATGCATATCCACATGTGCTCAGGGAATATCC 1346
Db 53656 GTGTACTAATACAGACTATGTCAACCAATGCATATCCACATGTGCTCAGGGAATATCC 53715
QY 1347 AGAAAACTGTGGGTAGACACTTGTACTCTCCAGAAAGCTCATCTCAGCTCCCTGAAAAAT 1406
Db 53716 AGAAAACTGTGGGTAGACACTTGTACTCTCCAGAAAGCTCATCTCAGCTCCCTGAAAAAT 53775
QY 1407 GCTCATTAACCTGTGCTTAATCTCTCTTTTCTAGTCTTTCATATATTTCTCACTCAATCTC 1466
Db 53776 GCTCATTAACCTGTGCTTAATCTCTCTTTTCTAGTCTTTCATATATTTCTCACTCAATCTC 53835
QY 1467 TGATCTGTCAATGTCTTGAATCAAGGCCAGCTGAGGTGAAGAGAAATGTGACAG. 1526
Db 53836 TGATCTGTCAATGTCTTGAATCAAGGCCAGCTGAGGTGAAGAGAAATGTGACAG 53895
QY 1527 GCACATGAATGGGAGTGAGGATAGTGGGTGAGGCTGAGAGGAGAGGAGAGAC 1586
Db 53896 GCACATGAATGGGAGTGAGGATAGTGGGTGAGGCTGAGAGGAGAGGAGAGAC 53955
QY 1587 ATGAGCATGCTGAGGCTTGACAAAGACAAAGGTGAGCAAGGGCTCACCATTCAGCCA 1646
Db 53956 ATGAGCATGCTGAGGCTTGACAAAGACAAAGGTGAGCAAGGGCTCACCATTCAGCCA 54015
QY 1647 GGAGATGATGACTGCTTACGCCATCTGCCAGCTGATTAACCTTGAAGGTTTCAAC 1706
Db 54016 GGAGATGATGACTGCTTACGCCATCTGCCAGCTGATTAACCTTGAAGGTTTCAAC 54075
QY 1707 AGTTCAGGAGAGTTTGGGAACCTGCAATAACCTGGGAGTTTGGTGAGTCCGATGATTC 1766
Db 54076 AGTTCAGGAGAGTTTGGGAACCTGCAATAACCTGGGAGTTTGGTGAGTCCGATGATTC 54135
QY 1767 TCTTTTGCATPAAGTGCATGACATATTTTGTCTTTTATTTACAGTTTATCTATGGCCACCATG 1826
Db 54136 TCTTTTGCATPAAGTGCATGACATATTTTGTCTTTTATTTACAGTTTATCTATGGCCACCATG 54195
QY 1827 CACCTTACATTTGAATCTATGATATATGCTCCATGTTCTCAGATGCTTCTTAGGCCA 1886
Db 54196 CACCTTACATTTGAATCTATGATATATGCTCCATGTTCTCAGATGCTTCTTAGGCCA 54255
QY 1887 CATCCCTGCTCTAAAAATTCAGAAAAATTTTGTATTAAGAGATGCAATATCTATGATA 1946
Db 54256 CATCCCTGCTCTAAAAATTCAGAAAAATTTTGTATTAAGAGATGCAATATCTATGATA 54315
QY 1947 TGCTTAATATATGATATGCAATATAA 1973
Db 54316 TGCTTAATATATGATATGCAATATAA 54342

RESULT 9

ABL32334

ID ABL32334 standard; DNA; 10528 BP.

XX ABL32334;

XX ABL32334;

XX ABL32334;

XX ABL32334;

XX ABL32334;

XX ABL32334;

XX ABL32334;

XX ABL32334;

XX ABL32334;

XX ABL32334;

XX ABL32334;

XX ABL32334;

XX ABL32334;

XX ABL32334;

XX ABL32334;

XX ABL32334;

XX ABL32334;

XX ABL32334;

neurofibromatosis; rheumatoid arthritis; psoriasis; bowel disease;
gene; ds.
Homo sapiens.
WO200200928-A2.
03-JAN-2002.
02-JUL-2001; 2001WO-EP07537.
30-JUN-2000; 2000DE-1032529.
01-SEP-2000; 2000DE-1043826.
(EPIC-) EPICENOMICS AG.
Olek A, Piepenbrock C, Berlin K;
WPI; 2002-130909/17.
Nucleic acid comprising fragment of chemically modified gene, useful
for diagnosis and treatment of diseases associated with abnormal
cytosine methylation
Claim 1; SEQ ID NO 307; 32pp + Sequence Listing; German.
The present invention provides a number of human immune system associated
genes which are modified by the methylation of cytosines. The sequences
can be used in the diagnosis and treatment of immune system disorders,
including eye diseases such as retinopathy, neovascular glaucoma and
macular degeneration, arteriosclerosis, anemia, cancer, acute myeloid
leukemia, Alzheimer's disease, AIDS, epilepsy, neurofibromatosis,
rheumatoid arthritis, psoriasis and inflammatory/ulcerative bowel
diseases. The present sequence is a gene of the invention.
Sequence 10528 BP; 3072 A; 86 C; 2419 G; 4951 T; 0 other;
Query Match 66.3%; Score 1313; DB 24; Length 10528;
Best Local Similarity 79.7%; Pred. No. 0;
Matches 1550; Conservative 0; Mismatches 395; Indels 0; Gaps 0;
QY 29 GAACAGAGAAAGTGGATGAACAAGGAGCGATTTCCCGAGTACATCCACACATCTGTC 88
Db 8327 GAATAGAGAAAGTGGATGAACAAGGAGCGATTTCCCGAGTACATTTATATATGTTGT 8386
QY 89 CACATCTGTTCTCGGTTTATCAGAAATACCAACAGAGCGGTGAAGAGTCCACACCTT 148
Db 8387 TATATTCGTTTCGGTTTATAGAAATATTAACGAGCGGTGAAGAGTATTTATTTT 8446
QY 149 TTTTGATTATGATTACGGTGTCTCTGTCATAAAATTTGACGTGAAGCAAAATTTGGGCGCA 208
Db 8447 TTTTGATTATGATTACGGTGTCTCTGTCATAAAATTTGACGTGAAGCAAAATTTGGGCGCA 8506
QY 209 ACTCCTGCTCGGCTCTACTCGCTGTTCTATCTTCTGTTTGGGCAACATCTGCT 268
Db 8507 ATTTTGTGTTTCTGTTTATTTGTTTATTTGTTTGGGTAATATGTTGT 8566
QY 269 CGTCTCATCTTAATAAACTGCAAAAGCTGAAGTCTGACTGACATTTACCTGCTCAA 328
Db 8567 CGTTTATTTAATAAAATTTGAAAGTTGAAAGTTGTTGTTGTTTATTTATTTTAA 8626
QY 329 CTTGCCATCTCTGATCTGCTTTTCTTATTTACTCTCCCATTTGTTGGGCTCACTCTGCTGC 388
Db 8627 TTTGGTTATTTTGTGTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTT 8686
QY 389 AAATGAGTGGTCTTTGGGAATGCAATGCAAAATTTTACAGAGGCTCTATCACATCGG 448
Db 8687 AAATGAGTGGTCTTTGGGAATGCAATGCAAAATTTTATAGAGGCTCTATCACATCGG 8746
QY 449 TTATTTTGGGGAATCTTCTTCTCATCTCTCTGCAATTCGATAGATAGATCTGCTATTTGT 508
Db 8747 TTATTTTGGGGAATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTT 8806

CC including eye diseases such as retinopathy, neovascular glaucoma and
 CC macular degeneration, arteriosclerosis, anemia, cancer, acute myeloid
 CC leukemia, Alzheimer's disease, AIDS, epilepsy, neurofibromatosis,
 CC rheumatoid arthritis, psoriasis and inflammatory/ulcerative bowel
 CC diseases. The present sequence is a gene of the invention.

XX
 SQ Sequence 10528 BP; 2873 A; 86 C; 2164 G; 5405 T; 0 other;
 Query Match 65.0%; Score 1286.4; DB 24; Length 10528;
 Best Local Similarity 78.9%; Pred. No. 0;
 Matches 1533; Conservative 0; Mismatches 411; Indels 0; Gaps 0;
 QY 30 AACAGAGAGTGGATTGAACAGAGCGATTTCGCCAGTACATCCACAACTGCTGCC 89
 DB 2201 AACAAAAAATAAATAAACAAGCGATTTCGCCAGTACATCCACAACTATATCC 2142
 QY 90 ACATCTCGTCTCGGTTTATCAGAAATACCAACGAGCGGTGAAGAAGTACCACCTTT 149
 DB 2141 ACATCTCGTCTCGGTTTATCAGAAATACCAACGAGCGGTGAAGAAGTACCACCTTT 2082
 QY 150 TTGTATTATGATACGGTCTCCCTGTCTATATAATTTGAGCGAAGCAATGGGGCCCA 209
 DB 2081 TTATATTAATACGATACCTCCCTATCATAAATTTAAGTAAACAAATTAACCCAA 2022
 QY 210 CTCCTGCCCTCGCTACTCGCTGGTGTTCATCTTTGGTTTGTGGGCAACATGCTGTC 269
 DB 2021 CTCCTACCTCGCTACTCGCTAATATTCATCTTTAATTTTATAAACAATATTAATC 1962
 QY 270 GTCCCTCATCTTAATAAAGCTGCAAAAGCTGGAAGTGTGACTGACATTTACCTGCTCA 329
 DB 1961 GTCCCTCATCTTAATAAAGCTGCAAAAGCTGGAAGTGTGACTGACATTTACCTGCTCA 1902
 QY 330 CTGGCCATCTGATCTGCTTTTCTTATTAATCTCCCATTTGGGCTCACTGCTGCA 389
 DB 1901 CTAACCATCTAATCTACTTTTCTTATTAATCTCCCATTTAAACATCTACTATCA 1842
 QY 390 AATGAGTGGCTTTGGGAATGCAATGTCGAATTTTACAGGCTGTATCATCATCGT 449
 DB 1841 AATAAATAAATCTTTAAATACAAATACAAATTTTACAAACTATATCATCATCGAT 1782
 QY 450 TATTTTGGGGAATCTTCTTCATCATCTCTGACAAATCGATAGATACCTGGCTATGTC 509
 DB 1781 TATTTTAAAGCAATCTTCTCATCATCTCTGACAAATCGATAGATACCTGATATATC 1722
 QY 510 CATGCTGTGCTTTAAAGCCAGGAGCTGACCTTTGGGCTGTGACAACTGTCATC 569
 DB 1721 CATACTATATTTACTTTTAAACCAAAACGATCACCTTTAAATAATAAATAAATA 1562
 QY 570 ACCTGTTGCTGCTGTTGCTGCTGCTCCAGGAATCATCTTTACTAATGCCAGAAA 629
 DB 1661 ACCTAATTAATACTATATTTACTTTAATCCCAAAATCATCTTTACTAATACCAAAA 1602
 QY 630 GAAGATCTGTTTATGCTGTGCGCTTATTTTCCAGAGGAGTGAATAATTTCCACACA 689
 DB 1601 AAAAAATCTATATCTAATACCTTTATTTCCAGGAAATAAATAATTTCCACACA 1542
 QY 690 ATATGAGGAACATTTGGGCTGGTCTGCTGCTGCTCATGTCATGTCATCTGCTACTCG 749
 DB 1541 ATAATAAAACATTTTAAACAAATTAATCTACCGCTACTCATCAATATCTACTACTCG 1482
 QY 750 GGAATCTGAAACCCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 809
 DB 1481 AATATCTAAACCCCTACTTCGATATCGAAACGAAAAAATAAATAAATAAATAA 1422
 QY 810 GTATCTTACCATCATGTTTATCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 869
 DB 1421 ATCATCTTACCATCATGTTTATCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1362
 QY 870 CTCCTGAACACCTTCCAGGAATTTCTGCGCTGAGTAACTGTGAAGCACCAGTCAACTG 929
 DB 1361 CTCCTGAACACCTTCCAGGAATTTCTGCGCTGAGTAACTGTGAAGCACCAGTCAACTG 1302
 QY 930 GACCAAGCCAGGAGTACAGAGACTCTTGGGATGACTCTGCTGCTGCTGCTGCTGCTG 989

DB 1301 AACCAACCGCAATTAACAAAACTCTTAAATAACTACTACTACTACTACTACTACT 1242
 QY 990 ATCTATGCTTGGTGGGAGAGTTCAGAGGTATCTCTCGTGTCTTCTTCCGAAGCAC 1049
 DB 1241 ATCTATGCTTGGTGGGAGAGTTCAGAGGTATCTCTCGTGTCTTCTTCCGAAGCAC 1182
 QY 1050 ATCAACAGCGCTCTCGCAACAATGTCAGTTTCTCAGGGAGACAGTGGATGGAGTG 1109
 DB 1181 ATCAACAGCGCTCTCGCAACAATGTCAGTTTCTCAGGGAGACAGTGGATGGAGTG 1122
 QY 1110 ACTTCAACAAACACGCTTCCACTGGGAGCAGGAGTCTCGGCTGTTTATAAAGCAG 1169
 DB 1121 ACTTCAACAAACACGCTTCCACTTAAACAAACAAATACTCTGACTAATTTATAA 1062
 QY 1170 GAGCAGTGTGATGTTGTTTAAAGGAGATTAACAACTGTATATAAACAACAACTTCA 1229
 DB 1061 AAACAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1002
 QY 1230 AGGGTTTGTGAACAAATAGAAACCTGTAAGCAGGTGCCCAGGAACCTCAGGCTGTG 1289
 DB 1001 AAATTTATTAACAAATAAACCCTATAAACAATAACCAAAACCTCAAACTATATA 942
 QY 1290 TACTATACAGACTATGTCAACCAATGCATATCCAACTGTCTCAGGGAATTAATCCAGA 1349
 DB 941 TACTATACAACTATATCAACCAATGCATATCCAACTATATCAAAATAATTAATCCAAA 882
 QY 1350 AAAAAGTGGGTAGACATTTGACTCTCCAGAAAGCTCATCTCAGTCTCTGAAAAATGCC 1409
 DB 881 AAAAAGTGGGTAGACATTTGACTCTCCAGAAAGCTCATCTCAGTCTCTGAAAAATGCC 822
 QY 1410 TCATTAACCTGTGCTAATCTCTTTTCTAGTCTCTCATATAATTTCTCACTCAATCTCTGA 1469
 DB 821 TCATTAACCTGTGCTAATCTCTTTTCTAGTCTCTCATATAATTTCTCACTCAATCTCTAA 762
 QY 1470 TTTCTCAATGTCTGAAATCAAGGCGCTGAGAGTGAAGAGAAATGTGACAGGCA 1529
 DB 761 TTTCTCAATGTCTGAAATCAAGGCGCTGAGAGTGAAGAGAAATGTGACAGGCA 702
 QY 1530 CAGATGAAGTGGGTAGGAGTGTGGGCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAG 1589
 DB 701 CAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 642
 QY 1590 AGCATGCTGAGCTGGCAAGAGCAAGAGTGAAGAGGCTCAGGATTCAGCCAGGA 1649
 DB 641 AACATTAACCTTAAACCTTAAACCTTAAACCTTAAACCTTAAACCTTAAACCTTAA 582
 QY 1650 GATGATGCTGCTTACGCCCATCTGCCAGTGTATTTAACCCTTGAAGGCTTCACCA 1709
 DB 581 AATAATTAATCTTAAACCTTAAACCTTAAACCTTAAACCTTAAACCTTAAACCTTAA 522
 QY 1710 TCAGGGAGGTTTGGGAACCTGCAATAACCTGGGAGTGTGCTGAGTCCGATGATCTCT 1769
 DB 521 TCAAAAAAATTTAAACCTTAAACCTTAAACCTTAAACCTTAAACCTTAAACCTTAA 462
 QY 1770 TTTGCAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1829
 DB 461 TTTGCAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 402
 QY 1830 CTTTACATTTGAAATCTATGAATATCATGCTCCATTTGTTTGAAGTCTTCTTGAAGCCACAT 1889
 DB 401 CTTTACATTTGAAATCTATGAATATCATGCTCCATTTGTTTGAAGTCTTCTTGAAGCCACAT 342
 QY 1890 CCCCTGTCTAAAAATTCAGAAAAATTTTGTGTTTAAAGATGATGATGATGATGATGATGAT 1949
 DB 341 CCCCTGTCTAAAAATTCAGAAAAATTTTGTGTTTAAAGATGATGATGATGATGATGATGAT 282
 QY 1950 TAAATATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1973
 DB 281 TAAATATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 258

AAS12140
ID AAS12140 standard; DNA; 1083 BP.
XX AC AAS12140;
XX DT 04-DEC-2001 (first entry)
XX DE Human wild-type CCR2-64V polynucleotide.
XX KW Human; CCR2 receptor; CCR2-64I; CCR2-64V; gene therapy; atherosclerosis;
KW single nucleotide polymorphism; hypercholesterolaemia; ds.
XX OS Homo sapiens.
XX PN WO200162796-A1.
XX PD 30-AUG-2001.
XX PF 22-FEB-2001; 2001WO-GB00755.
XX PR 22-FEB-2000; 2000GB-0004183.
XX PA (SMK) SMITHKLINE BEECHAM PLC.
XX PI Valdes AM, Groot PHE, Spurr NK;
XX DR WPI; 2001-550086/61.
XX DR P-PSDB; AAU07614.
XX PT Diagnosing atherosclerosis or susceptibility to atherosclerosis in a
PT subject, by determining a single nucleotide polymorphism in specific
PT codon of a polynucleotide encoding human CCR2 receptor in genome of the
PT subject -
XX PS Claim 3; Page 20-21; 28pp; English.
XX CC The invention relates to diagnosing atherosclerosis (or susceptibility
CC to) in a subject by determining expression or activity of the human
CC CCR2-64I polypeptide (a polymorphic variant form of the human CCR2
CC receptor) or the CCR2-64V polypeptide (human CCR2 receptor), by screening
CC for a single nucleotide polymorphism in codon 64 of the polynucleotide
CC encoding the CCR2 receptor. This results in production of CCR2-64I,
CC whereby polymorphic variants are associated with a lower incidence of
CC atherosclerosis. The presence or amount of CCR2-64I/V in a sample can
CC also be analysed. The sequences of the invention can be used for
CC predicting the response of a patient to drug treatment, for predicting
CC the disease outcome in a patient and also for the production of a
CC treatment for hypercholesterolaemia. The sequence represents DNA encoding
CC the wild-type receptor polypeptide CCR2-64V.
XX SQ Sequence 1083 BP; 255 A; 260 C; 247 G; 321 T; 0 other;

Query Match 54.78; Score 1083; DB 22; Length 1083;
Best Local Similarity 100.0%; Pred. No. 9.6e-304;
Matches 1083; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 ATGCTGCCACATCGCTTCGCTTATCAGAAATACCAAGAGAGCGGTGAAGAGTC 140
DB 1 ATGCTGCCACATCGCTTCGCTTATCAGAAATACCAAGAGAGCGGTGAAGAGTC 60

QY 141 ACCACCTTTTGGATTATGATTAGGTGCTCCCTGTCTATAAATTTGACGTGAAGCAAAAT 200
DB 61 ACCACCTTTTGGATTATGATTAGGTGCTCCCTGTCTATAAATTTGACGTGAAGCAAAAT 120

QY 201 GGGGCCCAACTCCCTCGCTCTACTCGCTGGTGTTCATCTTTGGTTTGTGGGCAAC 260
DB 121 GGGGCCCAACTCCCTCGCTCTACTCGCTGGTGTTCATCTTTGGTTTGTGGGCAAC 180

QY 261 ATGCTGGTCTGCTCATCTTAATAAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGT 320
DB 181 ATGCTGGTCTGCTCATCTTAATAAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGT 240

QY 321 CTGCTCAACCTGGCCATCTCTGATCTCTTTTCTTATTAATCTCCCAATTTGGGCTCAC 380

DB 241 CTGCTCAACCTGGCCATCTCTGATCTGCTTTTCTTATTAATCTCCCATCTGGGCTCAC 300
QY 381 TCTGCTGCAAAATGAGTGGGTCTTTTGGGAATGCAATGCAAAATTAATTAATTAATTAATTAAT 440
DB 301 TCTGCTGCAAAATGAGTGGGTCTTTTGGGAATGCAATGCAAAATTAATTAATTAATTAATTAAT 360
QY 441 CACATCGGTATTTTGGGGAATCTTCTTCATCATCTCTGCAATTAATTAATTAATTAATTAAT 500
DB 361 CACATCGGTATTTTGGGGAATCTTCTTCATCATCTCTGCAATTAATTAATTAATTAATTAAT 420
QY 501 GCTATTGTCCATGCTGTTTGTGTTTAAAGCCAGACGCTACCTTTGGGTTGGTGGTGAACA 560
DB 421 GCTATTGTCCATGCTGTTTGTGTTTAAAGCCAGACGCTACCTTTGGGTTGGTGGTGAACA 480
QY 561 AGTGTGATCACCTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 620
DB 481 AGTGTGATCACCTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 600
QY 621 TGCCAGAAAGAGATTTCTGTTTATGCTGCTGGCCCTTATTTTCCAGAGGATCATCTTTACTAAA 680
DB 541 TGCCAGAAAGAGATTTCTGTTTATGCTGCTGGCCCTTATTTTCCAGAGGATCATCTTTACTAAA 600
QY 681 TTCCACACAATAATGAGGAACATTTTGGGCTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 740
DB 601 TTCCACACAATAATGAGGAACATTTTGGGCTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 660
QY 741 TGCTACTCGGGAATCTCTGAAACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 800
DB 661 TGCTACTCGGGAATCTCTGAAACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 720
QY 801 GCACTGAGAGTCATCTTCCACCATCATGATTTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 860
DB 721 GCACTGAGAGTCATCTTCCACCATCATGATTTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 780
QY 861 ATTGCTATTCCTGACACACCTTCCAGGAATTTCTGGGCTGAGTAACCTGTGAAAGCACC 920
DB 781 ATTGCTATTCCTGACACACCTTCCAGGAATTTCTGGGCTGAGTAACCTGTGAAAGCACC 840
QY 921 AGTCAACTGGACCAAGCCAGCGTACAGAGACTCTTGGATGACTGACTGACTGACTGACTGACT 980
DB 841 AGTCAACTGGACCAAGCCAGCGTACAGAGACTCTTGGATGACTGACTGACTGACTGACTGACT 900
QY 981 AATCCCATCATCTATGCTTGGTGGGAGAGTTTCTGAGAGTATCTCTCGGTGTTCTTC 1040
DB 901 AATCCCATCATCTATGCTTGGTGGGAGAGTTTCTGAGAGTATCTCTCGGTGTTCTTC 960
QY 1041 CGAAAGCACATCAACAGCGCTTCTGCAACAATGTCAGTTTCTACAGGAGACAGTG 1100
DB 961 CGAAAGCACATCAACAGCGCTTCTGCAACAATGTCAGTTTCTACAGGAGACAGTG 1020
QY 1101 GATGGAGTGAATCTCAACAAACACGCTTCCACTGGGAGCAGGAGTCTCGGCTGGTTTA 1160
DB 1021 GATGGAGTGAATCTCAACAAACACGCTTCCACTGGGAGCAGGAGTCTCGGCTGGTTTA 1080
QY 1161 TAA 1163
DB 1081 TAA 1083

RESULT 12
AAS12139
ID AAS12139 standard; DNA; 1083 BP.
XX AC AAS12139;
XX DT 04-DEC-2001 (first entry)
XX DE Human CCR2-64I polymorphic variant polynucleotide.
XX KW Human; CCR2 receptor; CCR2-64I; CCR2-64V; gene therapy; atherosclerosis;
KW single nucleotide polymorphism; hypercholesterolaemia; ds.
XX

PF 05-APR-2001; 2001WO-US11098.
XX
PR 07-APR-2000; 2000US-195747P.
XX
PA (AREN-) ARENA PHARM INC.
XX
XX Lehmann-Bruinsma K, Liao CW, Lin I;
XX
DR WPI; 2001-648759/74.
XX
DR P-PSDB; ABB56340.
XX
XX
PT Identifying agonists of G protein-coupled receptors (GPCRs) for use in
PT disease treatment, comprises contacting candidate compounds with
PT versions of GPCRs.
XX
PS Example 2; Page 273-274; 394pp; English.
XX
CC The invention relates to G protein-coupled receptors (GPCRs) for which
CC the endogenous ligand has been identified. Non-endogenous
CC constitutively activated versions of known GPCRs are used in the
CC invention for the direct identification of candidate compounds as
CC receptor agonists, inverse agonists or partial agonists. Such
CC agonists are useful as therapeutic agents for diseases or disorders
CC associated with GPCRs. The present sequence encodes a non-endogenous
CC version of a known human GPCR.
XX
SQ Sequence 1083 BP; 257 A; 260 C; 246 G; 320 T; 0 other;

Query Match 54.6%; Score 1079.8; DB 23; Length 1083;
Best Local Similarity 99.8%; Pred. No. 8.2e-303;
Matches 1081; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 81 ATGCTGTCACATCTCGTTCTCGGTTTATCAGAAATACCAACGAGCGGTGAAGAAGTC 140
DB 1 ATGCTGTCACATCTCGTTCTCGGTTTATCAGAAATACCAACGAGCGGTGAAGAAGTC 60
QY 141 ACCACTTTTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 200
DB 61 ACCACTTTTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 120
QY 201 GGGGCCCACTCTCGCTCCGCTCTACTCGTGGTGTTCATCTTTGTTTGGGCAAC 260
DB 121 GGGGCCCACTCTCGCTCCGCTCTACTCGTGGTGTTCATCTTTGTTTGGGCAAC 180
QY 261 ATGCTGGTCTGCTCATCTTAATAACTGCAAAAGCTGAAGTCTTGACTGACATTTAC 320
DB 181 ATGCTGGTCTGCTCATCTTAATAACTGCAAAAGCTGAAGTCTTGACTGACATTTAC 240
QY 321 CTGCTCAACCTGGCCATCTCTGATCTGCTTTTCTTATTTACTCTCCATGTTGGGCTAC 380
DB 241 CTGCTCAACCTGGCCATCTCTGATCTGCTTTTCTTATTTACTCTCCATGTTGGGCTAC 300
QY 381 TCTGCTCAAAATGAGTGGTCTTTGGGAATGCAATGTCAAATATTCACAGGCTGTAT 440
DB 301 TCTGCTCAAAATGAGTGGTCTTTGGGAATGCAATGTCAAATATTCACAGGCTGTAT 360
QY 441 CACATCGGTTATTTGGGGGAATCTTCTCATCTCCCTCCGACATCATGATACCTTG 500
DB 361 CACATCGGTTATTTGGGGGAATCTTCTCATCTCCCTCCGACATCATGATACCTTG 420
QY 501 GCTATTGTCATGCTGTTTGGTCTTTAAAGCCAGGACGGTCACTTTGGGGTGGTGACA 560
DB 421 GCTATTGTCATGCTGTTTGGTCTTTAAAGCCAGGACGGTCACTTTGGGGTGGTGACA 480
QY 561 AGTGTGATCACTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 620
DB 481 AGTGTGATCACTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 540
QY 621 TGGCAGAAAGAAATCTGTTTATGTTATGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 680
DB 541 TGGCAGAAAGAAATCTGTTTATGTTATGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 600
QY 681 TTCCACACAATAATGAGAACATTTGGGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 740

DB 601 TTCCACACAATAATGAGAACATTTGGGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 660
QY 741 TGCTACTCGGGAATCTGTAACACCTGCTTCGGTGTGCAACGAGAGAGAGAGAGAGAGAGAG 800
DB 661 TGCTACTCGGGAATCTGTAACACCTGCTTCGGTGTGCAACGAGAGAGAGAGAGAGAGAGAG 720
QY 801 GCAGTGAGAGTCACTTCCACCATCATGATGTTTACTTTCTTCTTCTGACTCCCTATAAC 860
DB 721 GCAAGAGAGTCACTTCCACCATCATGATGTTTACTTTCTTCTTCTGACTCCCTATAAC 780
QY 861 ATTGTCTATCTCTGTAACACCTTCCAGGAATCTTCGGCTGAGTAAGTGTGAAGACACC 920
DB 781 ATTGTCTATCTCTGTAACACCTTCCAGGAATCTTCGGCTGAGTAAGTGTGAAGACACC 840
QY 921 AGTCAACTGGCAACGCCAGCGAGTGACAGAGACTCTTGGGATGACTCACTGCTGCATC 980
DB 841 AGTCAACTGGCAACGCCAGCGAGTGACAGAGACTCTTGGGATGACTCACTGCTGCATC 900
QY 981 AATCCATCATCTATGCTTCTGTTGGGAGAGTTTCAAGAGTATCTCTCGGTGTTCTTC 1040
DB 901 AATCCATCATCTATGCTTCTGTTGGGAGAGTTTCAAGAGTATCTCTCGGTGTTCTTC 960
QY 1041 CGAAAGCACATCACCAGCGCTTCTGCAACAATGTCCAGTTTCTACAGGAGACAGTG 1100
DB 961 CGAAAGCACATCACCAGCGCTTCTGCAACAATGTCCAGTTTCTACAGGAGACAGTG 1020
QY 1101 GATGAGTGAATCAACAACACCGCTTCCACTGGGAGAGAGAGTCTCGGTGTTCTTC 1160
DB 1021 GATGAGTGAATCAACAACACCGCTTCCACTGGGAGAGAGAGTCTCGGTGTTCTTC 1080
QY 1161 TAA 1163
DB 1081 TAA 1083
RESULT 14
AAT96976
ID AAT96976 standard; cDNA; 1083 BP.
XX AC AAT96976;
XX AC AAT96976;
DT 27-FEB-1998 (first entry)
XX Human monocyte chemoattractant protein 1 receptor encoding cDNA.
DE Human; MCP-1; monocyte chemoattractant protein; receptor; tumour;
KW inflammatory disease; viral; allergy; diabetes; ds.
XX Homo sapiens.
FH Key Location/Qualifiers
FT 1..1083
FT /*tag= a
FT /product= Monocyte_chemoattractant_protein_1_receptor
XX JP09238688-A.
XX 16-SEP-1997.
XX 11-MAR-1996; 96JP-0053574.
XX 11-MAR-1996; 96JP-0053574.
XX (TAKE) TAKEDA CHEM IND LTD.
XX WPI: 1997-506557/47.
XX P-PSDB; AAW35833.
XX DNA encoding human monocyte chemoattractant protein 1 receptor -
XX used to treat tumours and inflammatory, viral, infectious, allergic,
XX diabetic and central nervous system diseases

CC tail of the MCP-1R protein. The two sequences are denoted MCP-1RA
CC and MCP-1RB (see Q96297/R79165 & Q96298/R79166). Active mature
CC MCP-1RA has a predicted mol. wt. of about 42,000 daltons. MCP-1RB
XX has a mol. wt. of about 41,000 daltons.

SQ Sequence 2232 BP; 602 A; 464 C; 508 G; 658 T; 0 other;

Query Match 49.5%; Score 980; DB 16; Length 2232;
Best Local Similarity 100.0%; Pred. No. 1.2e-273;
Matches 980; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 42 GGATTGAACAAGCAGCATTTCCCGAGTACATCACAAACATGCTGTCACATCTCGTTCT 101
DB 1 GGATTGAACAAGCAGCATTTCCCGAGTACATCACAAACATGCTGTCACATCTCGTTCT 60
QY 102 CGTTTATCAGAATACCAACGAGAGCGGTGAAGAAGTACCACCTTTTGTGATTATGAT 161
DB 61 CGTTTATCAGAATACCAACGAGAGCGGTGAAGAAGTACCACCTTTTGTGATTATGAT 120
QY 162 TAGGGTCTCCCTGCTATTAATTTGACGTGAAGCAAAATGGGGCCCAACTCCTGCCTCCG 221
DB 121 TAGGGTCTCCCTGCTATTAATTTGACGTGAAGCAAAATGGGGCCCAACTCCTGCCTCCG 180
QY 222 CTCCTACTCGCTGGTGTTCATCTTTGTTTGTGGCAACATGCTGTCGTCCTCATCTTA 281
DB 181 CTCCTACTCGCTGGTGTTCATCTTTGTTTGTGGCAACATGCTGTCGTCCTCATCTTA 240
QY 282 ATAACTGCAAAAGCTGAAGTGCCTGACTGACATTTACCTGCTCAACCTGGCCATCTCT 341
DB 241 ATAACTGCAAAAGCTGAAGTGCCTGACTGACATTTACCTGCTCAACCTGGCCATCTCT 300
QY 342 GATCTGCTTTTCTTATTACTCTCCCATTTGTTGGGCTCACTCTGCTGCAAAATGAGTGGTC 401
DB 301 GATCTGCTTTTCTTATTACTCTCCCATTTGTTGGGCTCACTCTGCTGCAAAATGAGTGGTC 360
QY 402 TTGGGAATGCAATGTGCAAAATTTACAGGGCTGTATCACATCGSTTATTTTGGCGGA 461
DB 361 TTGGGAATGCAATGTGCAAAATTTACAGGGCTGTATCACATCGSTTATTTTGGCGGA 420
QY 462 ATCTTCTTCAATCCTCTGCAATGATACCTGGCTATTTGCTGCTGCAAAATGAGTGGTC 521
DB 421 ATCTTCTTCAATCCTCTGCAATGATACCTGGCTATTTGCTGCTGCAAAATGAGTGGTC 480
QY 522 GCTTTAAAGCCAGGACGGTCACTTTGGGGTGTGACAAAGTGTGATCACCTGGTGGTG 581
DB 481 GCTTTAAAGCCAGGACGGTCACTTTGGGGTGTGACAAAGTGTGATCACCTGGTGGTG 540
QY 582 GCTGTGTTGCTTCTGTCCCGAATCATCTTTACTAAATGCCAGAAAGAAATTCCTTT 641
DB 541 GCTGTGTTGCTTCTGTCCCGAATCATCTTTACTAAATGCCAGAAAGAAATTCCTTT 600
QY 642 TATGCTGTGGCCCTTATTTCCAGGAGATGGAATATTTCCACACATAATGAGGAAC 701
DB 601 TATGCTGTGGCCCTTATTTCCAGGAGATGGAATATTTCCACACATAATGAGGAAC 660
QY 702 ATTTGGGGCTGRCCTGCCCTGCTCATATGGTCACTGCTACTCGGAATCCTGAA 761
DB 661 ATTTGGGGCTGRCCTGCCCTGCTCATATGGTCACTGCTACTCGGAATCCTGAA 720
QY 762 ACCCTGCTTGGTGTGAAAGCAGAAAGAGGATAGGGCAGTGAGAGTCACTTCCACC 821
DB 721 ACCCTGCTTGGTGTGAAAGCAGAAAGAGGATAGGGCAGTGAGAGTCACTTCCACC 780
QY 822 ATCATGATTTGTTTACTTCTCTCTGGACTCCCTATACATTGTCATTTCTCTGAACACC 881
DB 781 ATCATGATTTGTTTACTTCTCTCTGGACTCCCTATACATTGTCATTTCTCTGAACACC 840
QY 882 TTCAGGAATTTTCGGCTGAGTAACTGTGAAAGCAGCACTCACTGAGGACCCACG 941
DB 841 TTCAGGAATTTTCGGCTGAGTAACTGTGAAAGCAGCACTCACTGAGGACCCACG 900
QY 942 CAGGTGACAGACTCTTGGGATGACTCACTGCTGCAATCAATCCCATCATCTATGCTTC 1001
DB 1001 CAGGTGACAGACTCTTGGGATGACTCACTGCTGCAATCAATCCCATCATCTATGCTTC

DB 901 CAGGTGACAGACTCTTGGGATGACTCACTGCTGCAATCAATCCCATCATCTATGCTTC 960
QY 1002 GTTGGGAGAAAGTTCAAG 1021
DB 961 GTTGGGAGAAAGTTCAAG 980

Search completed: June 1, 2003, 16:20:26
Job time : 1414.56 secs